{
 "disease": "colorectal-cancer",
 "label": "Colorectal cancer",
 "url": "https://usebiotransfer.org/disease/colorectal-cancer/",
 "built": "2026-09-12",
 "facts_hash": {
  "answers": "5ecfdf571f99",
  "targets": "e5e37cf44e58"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-12",
  "trials": "2026-09-12"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "APC",
   "ensembl": "ENSG00000134982",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "KRAS",
   "ensembl": "ENSG00000133703",
   "n_drug_entries": 3,
   "n_distinct_drugs": 3,
   "drugs": {
    "ADAGRASIB": "APPROVAL",
    "SALIRASIB": "PHASE_2",
    "SOTORASIB": "APPROVAL"
   },
   "approved": [
    "ADAGRASIB",
    "SOTORASIB"
   ],
   "n_approved": 2,
   "approved_for": {
    "ADAGRASIB": [
     "non-small cell lung carcinoma"
    ],
    "SOTORASIB": [
     "non-small cell lung carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "SMAD4",
   "ensembl": "ENSG00000141646",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "BRAF",
   "ensembl": "ENSG00000157764",
   "n_drug_entries": 18,
   "n_distinct_drugs": 16,
   "drugs": {
    "ARQ-736": "PHASE_1",
    "BELVARAFENIB": "PHASE_2",
    "CEP-32496": "PHASE_1_2",
    "DABRAFENIB": "APPROVAL",
    "ENCORAFENIB": "APPROVAL",
    "LIFIRAFENIB": "PHASE_1_2",
    "LY-3009120": "PHASE_1",
    "NAPORAFENIB": "PHASE_3",
    "PLIXORAFENIB": "PHASE_2",
    "RAF-265": "PHASE_2",
    "REGORAFENIB": "APPROVAL",
    "RG-7256": "PHASE_1",
    "SORAFENIB": "APPROVAL",
    "TOVORAFENIB": "APPROVAL",
    "VEMURAFENIB": "APPROVAL",
    "XL-281": "PHASE_1_2"
   },
   "approved": [
    "DABRAFENIB",
    "ENCORAFENIB",
    "REGORAFENIB",
    "SORAFENIB",
    "TOVORAFENIB",
    "VEMURAFENIB"
   ],
   "n_approved": 6,
   "approved_for": {
    "DABRAFENIB": [
     "metastatic melanoma",
     "melanoma",
     "low grade glioma",
     "glioma"
    ],
    "ENCORAFENIB": [
     "melanoma",
     "colorectal neoplasm",
     "metastatic melanoma"
    ],
    "REGORAFENIB": [
     "colorectal cancer",
     "metastatic colorectal cancer",
     "colorectal neoplasm"
    ],
    "SORAFENIB": [
     "renal cell carcinoma",
     "hepatocellular carcinoma",
     "thyroid gland carcinoma"
    ],
    "TOVORAFENIB": [
     "glioma",
     "low grade glioma"
    ],
    "VEMURAFENIB": [
     "melanoma",
     "metastatic melanoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "EGFR",
   "ensembl": "ENSG00000146648",
   "n_drug_entries": 82,
   "n_distinct_drugs": 74,
   "drugs": {
    "ABIVERTINIB": "PHASE_3",
    "AC-480": "PHASE_2",
    "AEE-788": "PHASE_1_2",
    "AFATINIB": "APPROVAL",
    "AFATINIB DIMALEATE": "APPROVAL",
    "ALLITINIB": "PHASE_1",
    "AMIVANTAMAB": "APPROVAL",
    "AUMOLERTINIB": "APPROVAL",
    "AV-412": "PHASE_1",
    "AZD-3759": "PHASE_2_3",
    "AZD-4769": "PHASE_1",
    "BAFISONTAMAB": "PHASE_2",
    "BMS-690514": "PHASE_2",
    "BRIGATINIB": "APPROVAL",
    "CANERTINIB": "PHASE_2",
    "CEP-32496": "PHASE_1_2",
    "CETUXIMAB": "APPROVAL",
    "CETUXIMAB SAROTALOCAN": "APPROVAL",
    "CLN-081": "PHASE_3",
    "CUDC-101": "PHASE_1",
    "DACOMITINIB": "APPROVAL",
    "DEPATUXIZUMAB": "PHASE_2",
    "DEPATUXIZUMAB MAFODOTIN": "PHASE_3",
    "DULIGOTUZUMAB": "PHASE_2",
    "EPITINIB": "PHASE_1",
    "ERLOTINIB": "APPROVAL",
    "FALNIDAMOL": "PHASE_1",
    "FIRMONERTINIB": "PHASE_3",
    "FUTUXIMAB": "PHASE_3",
    "GC1118": "PHASE_2",
    "GEFITINIB": "APPROVAL",
    "ICOTINIB": "APPROVAL",
    "IMGATUZUMAB": "PHASE_2",
    "JNJ-26483327": "PHASE_1",
    "KBP5209": "PHASE_1",
    "LAPATINIB": "APPROVAL",
    "LAPATINIB DITOSYLATE": "APPROVAL",
    "LAZERTINIB": "APPROVAL",
    "LOSATUXIZUMAB VEDOTIN": "PHASE_1",
    "MAB-425": "UNKNOWN",
    "MATUZUMAB": "PHASE_2",
    "MAVELERTINIB": "PHASE_1_2",
    "MDX-447": "PHASE_1",
    "MOBOCERTINIB": "APPROVAL",
    "MODOTUXIMAB": "PHASE_2",
    "NAQUOTINIB": "PHASE_3",
    "NAZARTINIB": "PHASE_3",
    "NECITUMUMAB": "APPROVAL",
    "NERATINIB": "APPROVAL",
    "NIMOTUZUMAB": "APPROVAL",
    "OLMUTINIB": "APPROVAL",
    "OSIMERTINIB": "APPROVAL",
    "PANITUMUMAB": "APPROVAL",
    "PELITINIB": "PHASE_2",
    "PF-06459988": "PHASE_2",
    "PIMURUTAMAB": "PHASE_2_3",
    "PKI-166": "PHASE_2",
    "POZIOTINIB": "PHASE_3",
    "PYROTINIB": "PHASE_3",
    "RINDOPEPIMUT": "PHASE_3",
    "ROCILETINIB": "APPROVAL",
    "RUSERONTINIB": "PHASE_3",
    "S-222611": "PHASE_1",
    "SAPITINIB": "PHASE_2",
    "SIMOTINIB": "PHASE_1",
    "TAK-285": "PHASE_1",
    "TARLOXOTINIB": "PHASE_2",
    "TESEVATINIB": "PHASE_3",
    "THELIATINIB": "PHASE_1",
    "TOMUZOTUXIMAB": "PHASE_2",
    "TUXOBERTINIB": "PHASE_1_2",
    "VANDETANIB": "APPROVAL",
    "VARLITINIB": "PHASE_2_3",
    "ZALUTUMUMAB": "PHASE_3"
   },
   "approved": [
    "AFATINIB",
    "AFATINIB DIMALEATE",
    "AMIVANTAMAB",
    "AUMOLERTINIB",
    "BRIGATINIB",
    "CETUXIMAB",
    "CETUXIMAB SAROTALOCAN",
    "DACOMITINIB",
    "ERLOTINIB",
    "GEFITINIB",
    "ICOTINIB",
    "LAPATINIB",
    "LAPATINIB DITOSYLATE",
    "LAZERTINIB",
    "MOBOCERTINIB",
    "NECITUMUMAB",
    "NERATINIB",
    "NIMOTUZUMAB",
    "OLMUTINIB",
    "OSIMERTINIB",
    "PANITUMUMAB",
    "ROCILETINIB",
    "VANDETANIB"
   ],
   "n_approved": 23,
   "approved_for": {
    "AFATINIB": [
     "non-small cell lung carcinoma"
    ],
    "AFATINIB DIMALEATE": [
     "non-small cell lung carcinoma"
    ],
    "AMIVANTAMAB": [
     "non-small cell lung carcinoma"
    ],
    "AUMOLERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "BRIGATINIB": [
     "non-small cell lung carcinoma",
     "anaplastic large cell lymphoma"
    ],
    "CETUXIMAB": [
     "malignant tumor of neck",
     "squamous cell carcinoma",
     "colorectal adenocarcinoma",
     "colorectal carcinoma",
     "colorectal cancer",
     "head and neck neoplasm",
     "colorectal neoplasm"
    ],
    "CETUXIMAB SAROTALOCAN": [
     "head and neck cancer"
    ],
    "DACOMITINIB": [
     "non-small cell lung carcinoma"
    ],
    "ERLOTINIB": [
     "non-small cell lung carcinoma",
     "pancreatic neoplasm"
    ],
    "GEFITINIB": [
     "non-small cell lung carcinoma",
     "head and neck squamous cell carcinoma"
    ],
    "ICOTINIB": [],
    "LAPATINIB": [
     "breast cancer"
    ],
    "LAPATINIB DITOSYLATE": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "LAZERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "MOBOCERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "NECITUMUMAB": [
     "non-small cell lung carcinoma",
     "colorectal cancer",
     "non-small cell squamous lung carcinoma"
    ],
    "NERATINIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "NIMOTUZUMAB": [
     "head and neck cancer"
    ],
    "OLMUTINIB": [],
    "OSIMERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "PANITUMUMAB": [
     "colorectal cancer",
     "colorectal adenocarcinoma",
     "colorectal neoplasm"
    ],
    "ROCILETINIB": [],
    "VANDETANIB": [
     "thyroid gland carcinoma",
     "medullary thyroid gland carcinoma",
     "thyroid tumor"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "ERBB2",
   "ensembl": "ENSG00000141736",
   "n_drug_entries": 48,
   "n_distinct_drugs": 45,
   "drugs": {
    "AC-480": "PHASE_2",
    "AEE-788": "PHASE_1_2",
    "AFATINIB": "APPROVAL",
    "AFATINIB DIMALEATE": "APPROVAL",
    "ALLITINIB": "PHASE_1",
    "ANVATABART OPADOTIN": "PHASE_2_3",
    "AV-412": "PHASE_1",
    "BMS-690514": "PHASE_2",
    "CANERTINIB": "PHASE_2",
    "CP-724714": "PHASE_2",
    "CUDC-101": "PHASE_1",
    "DACOMITINIB": "APPROVAL",
    "DISITAMAB VEDOTIN": "PHASE_3",
    "ERTUMAXOMAB": "PHASE_2",
    "GANCOTAMAB": "PHASE_2_3",
    "HEMAY-022": "PHASE_3",
    "JNJ-26483327": "PHASE_1",
    "KBP5209": "PHASE_1",
    "KN-026": "PHASE_3",
    "LAPATINIB": "APPROVAL",
    "LAPATINIB DITOSYLATE": "APPROVAL",
    "MARGETUXIMAB": "APPROVAL",
    "MASOPROCOL": "APPROVAL",
    "MM-111": "PHASE_2",
    "MUBRITINIB": "PHASE_1",
    "NERATINIB": "APPROVAL",
    "PERTUZUMAB": "APPROVAL",
    "POZIOTINIB": "PHASE_3",
    "PYROTINIB": "PHASE_3",
    "S-222611": "PHASE_1",
    "SAPITINIB": "PHASE_2",
    "TAK-285": "PHASE_1",
    "TARLOXOTINIB": "PHASE_2",
    "TESEVATINIB": "PHASE_3",
    "TRASTUZUMAB": "APPROVAL",
    "TRASTUZUMAB BOTIDOTIN": "PHASE_3",
    "TRASTUZUMAB DERUXTECAN": "APPROVAL",
    "TRASTUZUMAB DUOCARMAZINE": "APPROVAL",
    "TRASTUZUMAB EMTANSINE": "APPROVAL",
    "TUCATINIB": "APPROVAL",
    "TUXOBERTINIB": "PHASE_1_2",
    "VANDETANIB": "APPROVAL",
    "VARLITINIB": "PHASE_2_3",
    "ZANIDATAMAB": "APPROVAL",
    "ZENOCUTUZUMAB": "APPROVAL"
   },
   "approved": [
    "AFATINIB",
    "AFATINIB DIMALEATE",
    "DACOMITINIB",
    "LAPATINIB",
    "LAPATINIB DITOSYLATE",
    "MARGETUXIMAB",
    "MASOPROCOL",
    "NERATINIB",
    "PERTUZUMAB",
    "TRASTUZUMAB",
    "TRASTUZUMAB DERUXTECAN",
    "TRASTUZUMAB DUOCARMAZINE",
    "TRASTUZUMAB EMTANSINE",
    "TUCATINIB",
    "VANDETANIB",
    "ZANIDATAMAB",
    "ZENOCUTUZUMAB"
   ],
   "n_approved": 17,
   "approved_for": {
    "AFATINIB": [
     "non-small cell lung carcinoma"
    ],
    "AFATINIB DIMALEATE": [
     "non-small cell lung carcinoma"
    ],
    "DACOMITINIB": [
     "non-small cell lung carcinoma"
    ],
    "LAPATINIB": [
     "breast cancer"
    ],
    "LAPATINIB DITOSYLATE": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "MARGETUXIMAB": [
     "HER2 positive breast carcinoma",
     "breast cancer"
    ],
    "MASOPROCOL": [
     "prostate cancer"
    ],
    "NERATINIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "PERTUZUMAB": [
     "breast cancer",
     "breast carcinoma",
     "breast neoplasm"
    ],
    "TRASTUZUMAB": [
     "breast cancer",
     "breast carcinoma",
     "gastric cancer",
     "gastric neoplasm",
     "breast neoplasm"
    ],
    "TRASTUZUMAB DERUXTECAN": [
     "breast cancer",
     "HER2 positive breast carcinoma",
     "breast neoplasm"
    ],
    "TRASTUZUMAB DUOCARMAZINE": [],
    "TRASTUZUMAB EMTANSINE": [
     "breast cancer",
     "breast carcinoma",
     "breast neoplasm"
    ],
    "TUCATINIB": [
     "HER2 positive breast carcinoma",
     "metastasis",
     "breast neoplasm",
     "breast cancer",
     "colorectal carcinoma",
     "breast carcinoma"
    ],
    "VANDETANIB": [
     "thyroid gland carcinoma",
     "medullary thyroid gland carcinoma",
     "thyroid tumor"
    ],
    "ZANIDATAMAB": [
     "biliary tract neoplasm"
    ],
    "ZENOCUTUZUMAB": [
     "non-small cell lung carcinoma",
     "pancreatic neoplasm"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "PIK3CA",
   "ensembl": "ENSG00000121879",
   "n_drug_entries": 32,
   "n_distinct_drugs": 31,
   "drugs": {
    "ALPELISIB": "APPROVAL",
    "APITOLISIB": "PHASE_2",
    "AZD-6482": "UNKNOWN",
    "BAY-1082439": "PHASE_1",
    "BGT-226": "PHASE_1_2",
    "BUPARLISIB": "PHASE_3",
    "COPANLISIB": "APPROVAL",
    "DACTOLISIB": "PHASE_3",
    "DS-7423": "PHASE_1",
    "FIMEPINOSTAT": "PHASE_2",
    "GEDATOLISIB": "PHASE_3",
    "GSK-1059615": "PHASE_1",
    "INAVOLISIB": "APPROVAL",
    "IZORLISIB": "PHASE_1_2",
    "OMIPALISIB": "PHASE_1",
    "PANULISIB": "PHASE_1",
    "PAXALISIB": "PHASE_2_3",
    "PF-04691502": "PHASE_2",
    "PICTILISIB": "PHASE_2",
    "PILARALISIB": "PHASE_2",
    "PKI-179": "PHASE_1",
    "RECILISIB": "PHASE_1",
    "SAMOTOLISIB": "PHASE_2",
    "SERABELISIB": "PHASE_2",
    "SF-1126": "PHASE_2",
    "SONOLISIB": "PHASE_2",
    "TASELISIB": "PHASE_3",
    "VOXTALISIB": "PHASE_2",
    "VS-5584": "PHASE_1",
    "WX-037": "PHASE_1",
    "ZSTK-474": "PHASE_1"
   },
   "approved": [
    "ALPELISIB",
    "COPANLISIB",
    "INAVOLISIB"
   ],
   "n_approved": 3,
   "approved_for": {
    "ALPELISIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "COPANLISIB": [
     "follicular lymphoma",
     "non-Hodgkin lymphoma",
     "neoplasm of mature B-cells"
    ],
    "INAVOLISIB": [
     "breast neoplasm"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "MLH1",
   "ensembl": "ENSG00000076242",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "MSH2",
   "ensembl": "ENSG00000095002",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "NTRK1",
   "ensembl": "ENSG00000198400",
   "n_drug_entries": 17,
   "n_distinct_drugs": 16,
   "drugs": {
    "ALTIRATINIB": "PHASE_1",
    "AZD-6918": "PHASE_1",
    "AZD-7451": "PHASE_1",
    "CENEGERMIN": "APPROVAL",
    "CEP-2563": "PHASE_1",
    "ENTRECTINIB": "APPROVAL",
    "GZ-389988": "PHASE_2",
    "LAROTRECTINIB": "APPROVAL",
    "LESTAURTINIB": "APPROVAL",
    "MILCICLIB": "PHASE_2",
    "PEGCANTRATINIB": "PHASE_2",
    "PLX-7486": "PHASE_1",
    "REGORAFENIB": "APPROVAL",
    "REPOTRECTINIB": "APPROVAL",
    "SELITRECTINIB": "PHASE_1",
    "TALETRECTINIB": "PHASE_3"
   },
   "approved": [
    "CENEGERMIN",
    "ENTRECTINIB",
    "LAROTRECTINIB",
    "LESTAURTINIB",
    "REGORAFENIB",
    "REPOTRECTINIB"
   ],
   "n_approved": 6,
   "approved_for": {
    "CENEGERMIN": [
     "keratitis",
     "eye disorder"
    ],
    "ENTRECTINIB": [
     "non-small cell lung carcinoma"
    ],
    "LAROTRECTINIB": [
     "metastasis"
    ],
    "LESTAURTINIB": [
     "acute myeloid leukemia by FAB classification"
    ],
    "REGORAFENIB": [
     "colorectal cancer",
     "metastatic colorectal cancer",
     "colorectal neoplasm"
    ],
    "REPOTRECTINIB": [
     "non-small cell lung carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "CEACAM5",
   "ensembl": "ENSG00000105388",
   "n_drug_entries": 5,
   "n_distinct_drugs": 5,
   "drugs": {
    "ARCITUMOMAB": "APPROVAL",
    "LABETUZUMAB": "PHASE_2",
    "LABETUZUMAB GOVITECAN": "PHASE_2",
    "MEDI-565": "PHASE_1",
    "TUSAMITAMAB RAVTANSINE": "PHASE_3"
   },
   "approved": [
    "ARCITUMOMAB"
   ],
   "n_approved": 1,
   "approved_for": {
    "ARCITUMOMAB": [
     "breast cancer",
     "radiologic finding",
     "colorectal neoplasm"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "CEA": {
    "n": 113,
    "n_observational": 11,
    "n_active": 35,
    "n_withdrawn": 6,
    "trials": [
     {
      "nct": "NCT03125343",
      "title": "Watch and Wait as Treatment for Patients With Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2023-11-07",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03659448",
      "title": "Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-04-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04743102",
      "title": "Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2023-02-21",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05240950",
      "title": "Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases",
      "status": "RECRUITING",
      "last_update": "2022-03-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05563922",
      "title": "Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma",
      "status": "RECRUITING",
      "last_update": "2022-10-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05904665",
      "title": "Circulating Tumor DNA Methylation Guided Postoperative Follow-up Strategy for Non-metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-09-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06010862",
      "title": "Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2023-11-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06043466",
      "title": "A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06126406",
      "title": "Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes\uff08CAR-T\uff09 for CEA Positive Advanced Malignant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2023-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06130826",
      "title": "Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06149481",
      "title": "Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06209099",
      "title": "Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-06-12",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06609551",
      "title": "ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study",
      "status": "RECRUITING",
      "last_update": "2024-09-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06663839",
      "title": "A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-10-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06769828",
      "title": "Ga-68-FAPI-46 PET for CRC Recurrence Detection in Elevated CEA",
      "status": "RECRUITING",
      "last_update": "2025-01-22",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06821048",
      "title": "Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-01-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07179692",
      "title": "CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07247396",
      "title": "CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases",
      "status": "RECRUITING",
      "last_update": "2025-11-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07416552",
      "title": "A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07462650",
      "title": "Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-03-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07549412",
      "title": "A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07589517",
      "title": "Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07669298",
      "title": "Active Surveillance vs Adjuvant Chemoradiotherapy for Locally Resected Intermediate-Risk T1 Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00001568",
      "title": "Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities",
      "status": "COMPLETED",
      "last_update": "2008-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003433",
      "title": "Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer",
      "status": "COMPLETED",
      "last_update": "2013-06-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004604",
      "title": "Biological Therapy in Treating Patients With Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-02-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00012246",
      "title": "Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract",
      "status": "TERMINATED",
      "last_update": "2013-05-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00027534",
      "title": "Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2014-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00027833",
      "title": "Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2014-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00028496",
      "title": "Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-01-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00040599",
      "title": "Safety Study of 90Y-hMN14 to Treat Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00041652",
      "title": "Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer",
      "status": "COMPLETED",
      "last_update": "2021-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00041691",
      "title": "Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery",
      "status": "TERMINATED",
      "last_update": "2021-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00081848",
      "title": "Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00088413",
      "title": "PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2019-04-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00088933",
      "title": "Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2014-03-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00091286",
      "title": "Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2020-03-30",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00103142",
      "title": "Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-10-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00128622",
      "title": "Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2012-11-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00154713",
      "title": "Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment",
      "status": "UNKNOWN",
      "last_update": "2005-09-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00185081",
      "title": "Imaging Colo-rectal Cancer Using a Two Step Antibody Technique in Nuclear Imaging",
      "status": "COMPLETED",
      "last_update": "2016-04-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00225641",
      "title": "Assessment of Frequency of Surveillance After Curative Resection in Patients With Stage II and III Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2015-12-22",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00228189",
      "title": "Carcinoembryonic Antigen-loaded Dendritic Cells in Advanced Colorectal Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2010-11-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00529984",
      "title": "A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies",
      "status": "COMPLETED",
      "last_update": "2012-07-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00645710",
      "title": "Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery",
      "status": "COMPLETED",
      "last_update": "2019-03-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00647153",
      "title": "Immunoscintigraphy Using Radiolabeled Monoclonal Antibody in Finding Tumor Cells in Patients With Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-11-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00673322",
      "title": "Trial of Second Generation Designer T Cells in Colorectal Carcinoma",
      "status": "TERMINATED",
      "last_update": "2016-06-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00860860",
      "title": "Study of Pretargeted Radioimmunotherapy of a Anti-CEA Bispecific Antibody and Lu177-labeled Peptide in Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2012-03-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00895323",
      "title": "Bispecific Antibody in Finding Tumor Cells in Patients With Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2013-09-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00924092",
      "title": "An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...",
      "status": "COMPLETED",
      "last_update": "2019-12-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00995202",
      "title": "Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-12-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01064375",
      "title": "Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2022-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01147965",
      "title": "QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA",
      "status": "COMPLETED",
      "last_update": "2025-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01205022",
      "title": "Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01212887",
      "title": "Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer",
      "status": "TERMINATED",
      "last_update": "2012-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01270698",
      "title": "Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01273402",
      "title": "Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2021-08-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01320683",
      "title": "Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2016-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01552226",
      "title": "Compare Preperitoneal Analgesia to Epidural Analgesia for Pain Control After Colon and Rectal Surgery",
      "status": "COMPLETED",
      "last_update": "2025-09-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01605318",
      "title": "Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2024-01-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01723306",
      "title": "Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas",
      "status": "SUSPENDED",
      "last_update": "2016-06-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01890213",
      "title": "Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-07-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01915472",
      "title": "A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2021-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02231086",
      "title": "Adjuvant HIPEC in High Risk Colon Cancer",
      "status": "COMPLETED",
      "last_update": "2021-09-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02280070",
      "title": "RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).",
      "status": "UNKNOWN",
      "last_update": "2014-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02293954",
      "title": "Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02300922",
      "title": "Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2022-08-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02346955",
      "title": "Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)",
      "status": "TERMINATED",
      "last_update": "2020-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02349724",
      "title": "A Clinical Research of CAR T Cells Targeting CEA Positive Cancer",
      "status": "UNKNOWN",
      "last_update": "2017-04-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02403505",
      "title": "Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02409472",
      "title": "Intensive Versus Minimal Surveillance of Patients With Resected Dukes B2-C Colorectal Carcinoma",
      "status": "COMPLETED",
      "last_update": "2015-04-09",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02416466",
      "title": "CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases",
      "status": "COMPLETED",
      "last_update": "2019-03-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02850536",
      "title": "CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer",
      "status": "COMPLETED",
      "last_update": "2021-10-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02959151",
      "title": "A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy",
      "status": "UNKNOWN",
      "last_update": "2016-11-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03050814",
      "title": "Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004",
      "status": "TERMINATED",
      "last_update": "2021-12-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03127098",
      "title": "QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",
      "status": "TERMINATED",
      "last_update": "2024-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03169777",
      "title": "QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC",
      "status": "WITHDRAWN",
      "last_update": "2025-02-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03220984",
      "title": "The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2017-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03337347",
      "title": "Clinical Significance of Detecting CEA and CK20 mRNA-positive Cells in Colorectal Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2019-10-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03384316",
      "title": "Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2020-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03413254",
      "title": "Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-02-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03563157",
      "title": "QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine",
      "status": "TERMINATED",
      "last_update": "2024-12-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03622437",
      "title": "Individual Follow-up After Rectal Cancer - Focus on the Needs of the Patient",
      "status": "COMPLETED",
      "last_update": "2022-06-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03682744",
      "title": "CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)",
      "status": "WITHDRAWN",
      "last_update": "2022-04-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03699332",
      "title": "Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin",
      "status": "UNKNOWN",
      "last_update": "2019-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03866239",
      "title": "A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma",
      "status": "TERMINATED",
      "last_update": "2024-08-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03993327",
      "title": "An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-06-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04348643",
      "title": "Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer",
      "status": "WITHDRAWN",
      "last_update": "2026-07-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04491955",
      "title": "Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers",
      "status": "COMPLETED",
      "last_update": "2025-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04513431",
      "title": "A Clinical Research of CAR T Cells Targeting CEA Positive Colorectal Cancer (CRC)",
      "status": "UNKNOWN",
      "last_update": "2020-08-14",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04642924",
      "title": "SGM-101 in Locally Advanced and Recurrent Rectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2020-11-24",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04737213",
      "title": "SGM-101 in Colorectal Lung Metastases",
      "status": "UNKNOWN",
      "last_update": "2021-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04755920",
      "title": "SGM-101 in Colorectal Brain Metastases.",
      "status": "UNKNOWN",
      "last_update": "2024-05-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04826003",
      "title": "Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment",
      "status": "COMPLETED",
      "last_update": "2025-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05161585",
      "title": "Evaluation of Circulating Tumor DNA Guided Surveillance Strategy of Stage III Colorectal Cancer: an Open, Prospective, Randomized Controlled Cohort Study",
      "status": "UNKNOWN",
      "last_update": "2021-12-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05245786",
      "title": "An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05310565",
      "title": "The Effects of Chiropractic in Adults With Colon Cancer",
      "status": "WITHDRAWN",
      "last_update": "2024-04-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05396300",
      "title": "A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05415475",
      "title": "Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05419011",
      "title": "Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05464030",
      "title": "Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05538195",
      "title": "Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05646030",
      "title": "Feasibility, Reliability, and Satisfaction of CEA Using Home Based (Automated) Capillary Blood Sampling",
      "status": "COMPLETED",
      "last_update": "2024-09-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05726864",
      "title": "A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05736731",
      "title": "A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-04-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06006390",
      "title": "CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-08-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06018714",
      "title": "Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study",
      "status": "UNKNOWN",
      "last_update": "2023-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06280690",
      "title": "SGM-101 Tumor Targeted Fluorescence Endoscopy in Rectal Polyps With Suspected T1 Adenocarcinoma or High Grade Dysplasia",
      "status": "UNKNOWN",
      "last_update": "2024-02-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06395337",
      "title": "Multimodal Imaging in Rectal Cancer & Pancreatic Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-05-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06665334",
      "title": "To Explore the Effect of Huaier Granule on the Negative Conversion Rate After the CEA Level Increases Again After Colorectal Cancer Surgery",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-10-31",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06806046",
      "title": "Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07413146",
      "title": "Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07545356",
      "title": "A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 23,
     "n_observational": 0,
     "n_active": 10,
     "n_withdrawn": 2,
     "trials": [
      {
       "nct": "NCT05240950",
       "title": "Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases",
       "status": "RECRUITING",
       "last_update": "2022-03-11",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06010862",
       "title": "Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2023-11-08",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06043466",
       "title": "A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2023-09-21",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06126406",
       "title": "Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes\uff08CAR-T\uff09 for CEA Positive Advanced Malignant Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2023-11-13",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06821048",
       "title": "Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2026-01-23",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07179692",
       "title": "CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2025-10-02",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07247396",
       "title": "CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases",
       "status": "RECRUITING",
       "last_update": "2025-11-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07462650",
       "title": "Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer",
       "status": "RECRUITING",
       "last_update": "2026-03-10",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07589517",
       "title": "Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer",
       "status": "RECRUITING",
       "last_update": "2026-05-15",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00673322",
       "title": "Trial of Second Generation Designer T Cells in Colorectal Carcinoma",
       "status": "TERMINATED",
       "last_update": "2016-06-17",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01723306",
       "title": "Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas",
       "status": "SUSPENDED",
       "last_update": "2016-06-14",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02349724",
       "title": "A Clinical Research of CAR T Cells Targeting CEA Positive Cancer",
       "status": "UNKNOWN",
       "last_update": "2017-04-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02416466",
       "title": "CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases",
       "status": "COMPLETED",
       "last_update": "2019-03-26",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02850536",
       "title": "CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer",
       "status": "COMPLETED",
       "last_update": "2021-10-21",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02959151",
       "title": "A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy",
       "status": "UNKNOWN",
       "last_update": "2016-11-08",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03682744",
       "title": "CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)",
       "status": "WITHDRAWN",
       "last_update": "2022-04-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04348643",
       "title": "Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer",
       "status": "WITHDRAWN",
       "last_update": "2026-07-10",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04513431",
       "title": "A Clinical Research of CAR T Cells Targeting CEA Positive Colorectal Cancer (CRC)",
       "status": "UNKNOWN",
       "last_update": "2020-08-14",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05396300",
       "title": "A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors",
       "status": "COMPLETED",
       "last_update": "2026-07-15",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05415475",
       "title": "Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors",
       "status": "COMPLETED",
       "last_update": "2026-07-09",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05538195",
       "title": "Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors",
       "status": "COMPLETED",
       "last_update": "2026-07-10",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05736731",
       "title": "A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-04-25",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06006390",
       "title": "CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors",
       "status": "UNKNOWN",
       "last_update": "2024-08-09",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CEA",
     "CEACAM5",
     "carcinoembryonic antigen",
     "tusamitamab",
     "labetuzumab",
     "cibisatamab"
    ]
   },
   "GUCY2C": {
    "n": 12,
    "n_observational": 0,
    "n_active": 5,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05319314",
      "title": "LYL273 for Patients With Relapsed or Refractory mCRC",
      "status": "RECRUITING",
      "last_update": "2026-06-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07417488",
      "title": "GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas",
      "status": "RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07462650",
      "title": "Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-03-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07589517",
      "title": "Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01972737",
      "title": "Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer",
      "status": "COMPLETED",
      "last_update": "2025-05-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03449030",
      "title": "A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)",
      "status": "TERMINATED",
      "last_update": "2021-03-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04111172",
      "title": "A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04171141",
      "title": "Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.",
      "status": "TERMINATED",
      "last_update": "2025-01-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05287165",
      "title": "Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms",
      "status": "UNKNOWN",
      "last_update": "2022-03-18",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05875402",
      "title": "XKDCT080 in GCC-positive Recurrent or Refractory Solid Tumors With Single Center, Single Arm, and Dose Escalation",
      "status": "UNKNOWN",
      "last_update": "2023-05-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06675513",
      "title": "Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer",
      "status": "SUSPENDED",
      "last_update": "2026-05-07",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07152210",
      "title": "Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2026-05-28",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 5,
     "n_observational": 0,
     "n_active": 2,
     "n_withdrawn": 1,
     "trials": [
      {
       "nct": "NCT07462650",
       "title": "Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer",
       "status": "RECRUITING",
       "last_update": "2026-03-10",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07589517",
       "title": "Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer",
       "status": "RECRUITING",
       "last_update": "2026-05-15",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05287165",
       "title": "Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms",
       "status": "UNKNOWN",
       "last_update": "2022-03-18",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06675513",
       "title": "Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer",
       "status": "SUSPENDED",
       "last_update": "2026-05-07",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07152210",
       "title": "Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer",
       "status": "WITHDRAWN",
       "last_update": "2026-05-28",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "GUCY2C",
     "guanylyl cyclase C",
     "guanylate cyclase C",
     "GCC"
    ]
   },
   "HER2": {
    "n": 137,
    "n_observational": 9,
    "n_active": 62,
    "n_withdrawn": 6,
    "trials": [
     {
      "nct": "NCT03740256",
      "title": "Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-02-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04025541",
      "title": "Analysis of Circulating Tumor Markers in Blood",
      "status": "RECRUITING",
      "last_update": "2025-04-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04842812",
      "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04899908",
      "title": "Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05253651",
      "title": "A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05672524",
      "title": "A Study of Tucatinib and Trastuzumab in People With Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05725200",
      "title": "Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2023-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05786716",
      "title": "DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations",
      "status": "RECRUITING",
      "last_update": "2025-12-02",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05824975",
      "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)",
      "status": "RECRUITING",
      "last_update": "2024-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05845450",
      "title": "Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05868226",
      "title": "PRE-ISPY Phase I/II Oncology Platform Program",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05969041",
      "title": "Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors",
      "status": "RECRUITING",
      "last_update": "2024-01-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06245356",
      "title": "Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-12-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06253871",
      "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06324357",
      "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06330064",
      "title": "A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06434597",
      "title": "A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.",
      "status": "RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06490536",
      "title": "The Sagittarius Trial",
      "status": "RECRUITING",
      "last_update": "2025-08-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06500052",
      "title": "A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-09-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06589830",
      "title": "TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06625775",
      "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06695845",
      "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06715839",
      "title": "Target-specific immunoPET Imaging of Digestive System Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-12-31",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06760819",
      "title": "A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07108127",
      "title": "Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07192068",
      "title": "Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.",
      "status": "RECRUITING",
      "last_update": "2025-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07216105",
      "title": "FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07318805",
      "title": "A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07334119",
      "title": "Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07405476",
      "title": "Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment",
      "status": "RECRUITING",
      "last_update": "2026-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07407465",
      "title": "Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.",
      "status": "RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07462650",
      "title": "Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-03-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07540572",
      "title": "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07589517",
      "title": "Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07630961",
      "title": "Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003995",
      "title": "Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2",
      "status": "COMPLETED",
      "last_update": "2013-02-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004074",
      "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu",
      "status": "COMPLETED",
      "last_update": "2013-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005842",
      "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006015",
      "title": "Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2013-05-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00031681",
      "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)",
      "status": "COMPLETED",
      "last_update": "2013-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00034281",
      "title": "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2",
      "status": "COMPLETED",
      "last_update": "2012-02-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00091286",
      "title": "Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2020-03-30",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00959946",
      "title": "Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer",
      "status": "TERMINATED",
      "last_update": "2013-02-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01376505",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-09-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01445054",
      "title": "111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer",
      "status": "TERMINATED",
      "last_update": "2019-03-11",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01576666",
      "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2020-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01862003",
      "title": "Phase I/II Trial of Antagonism of HER in GI Cancer",
      "status": "COMPLETED",
      "last_update": "2019-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02124148",
      "title": "A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2020-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02291289",
      "title": "A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)",
      "status": "COMPLETED",
      "last_update": "2024-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02318901",
      "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer",
      "status": "TERMINATED",
      "last_update": "2019-10-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02442414",
      "title": "A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02713984",
      "title": "A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer",
      "status": "WITHDRAWN",
      "last_update": "2020-03-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02900664",
      "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris\u00ae (Canakinumab) or Mekinist\u00ae (Trametinib)",
      "status": "COMPLETED",
      "last_update": "2022-03-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02983045",
      "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03043313",
      "title": "Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03169777",
      "title": "QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC",
      "status": "WITHDRAWN",
      "last_update": "2025-02-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03185988",
      "title": "Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System",
      "status": "UNKNOWN",
      "last_update": "2019-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03225937",
      "title": "Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03251378",
      "title": "A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers",
      "status": "COMPLETED",
      "last_update": "2024-09-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03288987",
      "title": "Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-01-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03319459",
      "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2021-11-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03323424",
      "title": "Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers",
      "status": "WITHDRAWN",
      "last_update": "2020-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03365882",
      "title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2026-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03384940",
      "title": "DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)",
      "status": "COMPLETED",
      "last_update": "2021-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03418558",
      "title": "Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.",
      "status": "UNKNOWN",
      "last_update": "2018-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03425773",
      "title": "Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care",
      "status": "COMPLETED",
      "last_update": "2020-02-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03457896",
      "title": "Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status",
      "status": "UNKNOWN",
      "last_update": "2022-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03563157",
      "title": "QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine",
      "status": "TERMINATED",
      "last_update": "2024-12-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03602079",
      "title": "Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene",
      "status": "COMPLETED",
      "last_update": "2023-08-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03803553",
      "title": "Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03821233",
      "title": "A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers",
      "status": "COMPLETED",
      "last_update": "2025-01-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03843749",
      "title": "Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.",
      "status": "UNKNOWN",
      "last_update": "2019-02-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03875313",
      "title": "Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2022-02-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03924466",
      "title": "Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients",
      "status": "UNKNOWN",
      "last_update": "2024-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03929666",
      "title": "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-09-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03970382",
      "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors",
      "status": "SUSPENDED",
      "last_update": "2022-08-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04042480",
      "title": "A Study of SGN-CD228A in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-03-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04172597",
      "title": "A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2024-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04209465",
      "title": "A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.",
      "status": "TERMINATED",
      "last_update": "2025-04-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04227041",
      "title": "A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2020-01-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04278144",
      "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-09-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04319757",
      "title": "ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-12-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04380012",
      "title": "A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2021-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04430738",
      "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04460456",
      "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2022-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04464967",
      "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers",
      "status": "WITHDRAWN",
      "last_update": "2021-05-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04482309",
      "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04485013",
      "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04513223",
      "title": "A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors",
      "status": "COMPLETED",
      "last_update": "2026-02-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04577963",
      "title": "A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-07-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04579380",
      "title": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04584008",
      "title": "Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644068",
      "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04660929",
      "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04665921",
      "title": "A Study of SGN-STNV in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-02-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04704661",
      "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04744831",
      "title": "Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05039944",
      "title": "SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies",
      "status": "TERMINATED",
      "last_update": "2024-07-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05041972",
      "title": "ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)",
      "status": "WITHDRAWN",
      "last_update": "2022-09-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05062889",
      "title": "Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients",
      "status": "SUSPENDED",
      "last_update": "2026-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05091528",
      "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers",
      "status": "TERMINATED",
      "last_update": "2022-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05162755",
      "title": "S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers",
      "status": "COMPLETED",
      "last_update": "2026-05-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05193292",
      "title": "Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2022-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05333809",
      "title": "Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2022-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05350917",
      "title": "Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy",
      "status": "UNKNOWN",
      "last_update": "2022-05-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05356897",
      "title": "Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study",
      "status": "WITHDRAWN",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05382364",
      "title": "Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05395052",
      "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05493683",
      "title": "Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2022-10-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05514717",
      "title": "A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2",
      "status": "TERMINATED",
      "last_update": "2026-06-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05515796",
      "title": "Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors",
      "status": "COMPLETED",
      "last_update": "2026-04-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05576077",
      "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05578287",
      "title": "RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05661357",
      "title": "Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression",
      "status": "UNKNOWN",
      "last_update": "2024-04-17",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05673512",
      "title": "To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-02-20",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05785325",
      "title": "RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05985707",
      "title": "KN026 Plus Chemotherapy \u00b1 KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06136897",
      "title": "Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06328738",
      "title": "ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06349044",
      "title": "A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.",
      "status": "UNKNOWN",
      "last_update": "2024-08-27",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06625515",
      "title": "First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers",
      "status": "TERMINATED",
      "last_update": "2026-02-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07021378",
      "title": "Tolerance to Immunomodulatory Nutritional Therapy in Oncology Patients Undergoing Chemotherapy and Radiotherapy",
      "status": "COMPLETED",
      "last_update": "2025-06-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07036185",
      "title": "A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07059338",
      "title": "Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07243938",
      "title": "Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-11-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07318389",
      "title": "ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07384377",
      "title": "JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07483684",
      "title": "A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07509424",
      "title": "Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07631871",
      "title": "An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07631884",
      "title": "Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07653685",
      "title": "A Clinical Study of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in the Treatment of Advanced Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07691489",
      "title": "A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07730489",
      "title": "A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07768358",
      "title": "Tucatinib Continuation Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07796763",
      "title": "A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 6,
     "n_observational": 0,
     "n_active": 3,
     "n_withdrawn": 1,
     "trials": [
      {
       "nct": "NCT04842812",
       "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2024-06-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07462650",
       "title": "Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer",
       "status": "RECRUITING",
       "last_update": "2026-03-10",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07589517",
       "title": "Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer",
       "status": "RECRUITING",
       "last_update": "2026-05-15",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02713984",
       "title": "A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer",
       "status": "WITHDRAWN",
       "last_update": "2020-03-19",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02983045",
       "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
       "status": "COMPLETED",
       "last_update": "2023-03-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03970382",
       "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors",
       "status": "SUSPENDED",
       "last_update": "2022-08-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "HER2",
     "ERBB2",
     "trastuzumab",
     "tucatinib"
    ]
   },
   "EGFR": {
    "n": 445,
    "n_observational": 47,
    "n_active": 124,
    "n_withdrawn": 19,
    "trials": [
     {
      "nct": "NCT02885753",
      "title": "Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver",
      "status": "RECRUITING",
      "last_update": "2025-07-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03526835",
      "title": "A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740256",
      "title": "Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-02-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04235114",
      "title": "Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)",
      "status": "RECRUITING",
      "last_update": "2024-01-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04429542",
      "title": "Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04687631",
      "title": "Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases",
      "status": "RECRUITING",
      "last_update": "2024-12-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04842812",
      "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05007132",
      "title": "Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05107674",
      "title": "A Study of NX-1607 in Adults With Advanced Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05725200",
      "title": "Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2023-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05786924",
      "title": "Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05797467",
      "title": "Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients",
      "status": "RECRUITING",
      "last_update": "2023-05-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05845450",
      "title": "Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05863195",
      "title": "Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05868226",
      "title": "PRE-ISPY Phase I/II Oncology Platform Program",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05959356",
      "title": "Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05962502",
      "title": "Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy",
      "status": "RECRUITING",
      "last_update": "2023-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05985954",
      "title": "Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06207656",
      "title": "Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-10-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06226857",
      "title": "Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-01-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06245356",
      "title": "Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-12-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06252649",
      "title": "Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-na\u00efve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06253871",
      "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06321081",
      "title": "ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06411600",
      "title": "Combination Therapy for BRAF-V600E Metastatic CRCm",
      "status": "RECRUITING",
      "last_update": "2024-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06412198",
      "title": "A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations",
      "status": "RECRUITING",
      "last_update": "2026-06-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06440902",
      "title": "Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA",
      "status": "RECRUITING",
      "last_update": "2024-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06490536",
      "title": "The Sagittarius Trial",
      "status": "RECRUITING",
      "last_update": "2025-08-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06509126",
      "title": "Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-07-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06540326",
      "title": "Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab",
      "status": "RECRUITING",
      "last_update": "2025-12-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06542588",
      "title": "Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC",
      "status": "RECRUITING",
      "last_update": "2024-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06586515",
      "title": "MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06682793",
      "title": "A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression",
      "status": "RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06714357",
      "title": "ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06715839",
      "title": "Target-specific immunoPET Imaging of Digestive System Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-12-31",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06720987",
      "title": "A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06728072",
      "title": "Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06760819",
      "title": "A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06764771",
      "title": "A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06820463",
      "title": "A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06835569",
      "title": "A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations",
      "status": "RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06841159",
      "title": "Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1\uff0cChemotherapy and Target Therapy for Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-02-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06856187",
      "title": "Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06917079",
      "title": "BBO-11818 in Adult Subjects With KRAS Mutant Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06922383",
      "title": "A Clinical Study of Arfolitixorin in Patients With mCRC",
      "status": "RECRUITING",
      "last_update": "2026-06-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06978400",
      "title": "A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-05-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06983743",
      "title": "A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07012954",
      "title": "ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC",
      "status": "RECRUITING",
      "last_update": "2025-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07020221",
      "title": "A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07044908",
      "title": "TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07044921",
      "title": "Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.",
      "status": "RECRUITING",
      "last_update": "2025-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07094113",
      "title": "AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07094204",
      "title": "A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07201519",
      "title": "Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy",
      "status": "RECRUITING",
      "last_update": "2026-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07216105",
      "title": "FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07253896",
      "title": "Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab",
      "status": "RECRUITING",
      "last_update": "2025-11-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07318805",
      "title": "A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07411599",
      "title": "Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial (\"Chip-CRC Trial\")",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07474727",
      "title": "A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07503756",
      "title": "JS212 Combination Therapies in Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07543744",
      "title": "A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix\u00ae in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07549399",
      "title": "SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC",
      "status": "RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07589205",
      "title": "Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07659795",
      "title": "A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07702032",
      "title": "Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07724223",
      "title": "Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC",
      "status": "RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07790510",
      "title": "HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004879",
      "title": "Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer",
      "status": "COMPLETED",
      "last_update": "2013-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005076",
      "title": "Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-04-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00020930",
      "title": "Cetuximab in Treating Patients With Stage IV Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2009-12-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00039273",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00044343",
      "title": "GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin",
      "status": "COMPLETED",
      "last_update": "2014-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00044863",
      "title": "Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma",
      "status": "COMPLETED",
      "last_update": "2011-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00056030",
      "title": "Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-01-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00061815",
      "title": "Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2010-04-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00063141",
      "title": "Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2010-04-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00077298",
      "title": "Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00079066",
      "title": "Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-08-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00079274",
      "title": "Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer",
      "status": "COMPLETED",
      "last_update": "2026-06-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00083616",
      "title": "Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2014-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00083720",
      "title": "Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2011-05-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00089635",
      "title": "Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2022-11-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101348",
      "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer",
      "status": "COMPLETED",
      "last_update": "2014-06-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101894",
      "title": "Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2012-09-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00111761",
      "title": "Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-12-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00111774",
      "title": "Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma",
      "status": "COMPLETED",
      "last_update": "2013-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00113763",
      "title": "Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2022-11-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00113776",
      "title": "Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2011-01-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00115765",
      "title": "PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study",
      "status": "COMPLETED",
      "last_update": "2018-10-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00125034",
      "title": "Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)",
      "status": "COMPLETED",
      "last_update": "2014-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00154102",
      "title": "Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)",
      "status": "COMPLETED",
      "last_update": "2017-01-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00182715",
      "title": "Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2013-09-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00226941",
      "title": "A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer",
      "status": "TERMINATED",
      "last_update": "2017-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00227734",
      "title": "Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2012-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00254137",
      "title": "Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.",
      "status": "COMPLETED",
      "last_update": "2010-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00265850",
      "title": "Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-08-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00286130",
      "title": "Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2012-05-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00297128",
      "title": "Preoperative Chemoradiation With Capecitabine and Cetuximab",
      "status": "COMPLETED",
      "last_update": "2011-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00309179",
      "title": "A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00324415",
      "title": "Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00326495",
      "title": "BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00327119",
      "title": "Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2009-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00332163",
      "title": "Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy",
      "status": "COMPLETED",
      "last_update": "2016-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00336856",
      "title": "Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy",
      "status": "COMPLETED",
      "last_update": "2016-07-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00339183",
      "title": "Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone",
      "status": "COMPLETED",
      "last_update": "2022-09-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00346099",
      "title": "Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum",
      "status": "WITHDRAWN",
      "last_update": "2008-01-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00353457",
      "title": "Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma",
      "status": "TERMINATED",
      "last_update": "2020-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00362102",
      "title": "A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-11-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00364013",
      "title": "PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy",
      "status": "COMPLETED",
      "last_update": "2022-11-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00383695",
      "title": "Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2010-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00389870",
      "title": "Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil",
      "status": "COMPLETED",
      "last_update": "2022-06-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00397384",
      "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00411450",
      "title": "Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment",
      "status": "COMPLETED",
      "last_update": "2016-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00418938",
      "title": "SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial",
      "status": "COMPLETED",
      "last_update": "2018-10-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00419159",
      "title": "Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2019-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00422773",
      "title": "Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2009-02-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00425204",
      "title": "Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment",
      "status": "COMPLETED",
      "last_update": "2008-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00437268",
      "title": "A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2020-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00438737",
      "title": "Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2011-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00439517",
      "title": "Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.",
      "status": "COMPLETED",
      "last_update": "2014-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00466505",
      "title": "Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2012-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00475293",
      "title": "Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC",
      "status": "COMPLETED",
      "last_update": "2013-09-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00478634",
      "title": "A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2012-11-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00501410",
      "title": "FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-08-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00503685",
      "title": "Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy",
      "status": "COMPLETED",
      "last_update": "2018-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00508404",
      "title": "Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00510627",
      "title": "Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases",
      "status": "WITHDRAWN",
      "last_update": "2017-03-03",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00522665",
      "title": "Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-05-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00538291",
      "title": "Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment",
      "status": "TERMINATED",
      "last_update": "2014-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00559741",
      "title": "Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2011-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00563316",
      "title": "Effect of Panitumumab on the Pharmacokinetics of Irinotecan",
      "status": "COMPLETED",
      "last_update": "2016-04-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00594984",
      "title": "Phase I/II Combination With Irinotecan- Erbitux",
      "status": "COMPLETED",
      "last_update": "2015-11-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00622674",
      "title": "Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00628368",
      "title": "Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-02-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00630786",
      "title": "Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study",
      "status": "COMPLETED",
      "last_update": "2014-02-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00637091",
      "title": "Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions",
      "status": "COMPLETED",
      "last_update": "2021-01-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00640081",
      "title": "Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00647530",
      "title": "Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery",
      "status": "UNKNOWN",
      "last_update": "2019-05-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00655499",
      "title": "Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00671372",
      "title": "A Study of Dulanermin Administered in Combination With Camptosar\u00ae/Erbitux\u00ae Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2016-11-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00677924",
      "title": "Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2023-07-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00719199",
      "title": "Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2013-10-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00725400",
      "title": "Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2011-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00766220",
      "title": "Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver",
      "status": "WITHDRAWN",
      "last_update": "2013-01-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00784667",
      "title": "Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib",
      "status": "UNKNOWN",
      "last_update": "2010-11-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00788957",
      "title": "Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)",
      "status": "COMPLETED",
      "last_update": "2024-08-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00792363",
      "title": "Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations",
      "status": "COMPLETED",
      "last_update": "2012-06-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00814619",
      "title": "Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer",
      "status": "COMPLETED",
      "last_update": "2014-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00819780",
      "title": "PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors",
      "status": "COMPLETED",
      "last_update": "2022-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00820417",
      "title": "Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib",
      "status": "COMPLETED",
      "last_update": "2009-01-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00841191",
      "title": "A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2014-05-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00842257",
      "title": "Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-05-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00845039",
      "title": "A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab",
      "status": "TERMINATED",
      "last_update": "2018-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00853931",
      "title": "Biomarker - Panitumumab Response With KRAS Wild Type MCC",
      "status": "COMPLETED",
      "last_update": "2015-12-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00867334",
      "title": "New Individualized Therapy Trial for Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2020-06-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00879385",
      "title": "KRAS Wild-type Metastatic Colorectal Cancer Trial",
      "status": "COMPLETED",
      "last_update": "2014-10-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00885885",
      "title": "Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases",
      "status": "COMPLETED",
      "last_update": "2017-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00891930",
      "title": "Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab",
      "status": "COMPLETED",
      "last_update": "2024-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00925015",
      "title": "Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)",
      "status": "COMPLETED",
      "last_update": "2018-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00940316",
      "title": "Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00950820",
      "title": "Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2013-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00954876",
      "title": "Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2022-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00958386",
      "title": "Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)",
      "status": "COMPLETED",
      "last_update": "2015-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00967655",
      "title": "Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2014-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00972881",
      "title": "Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-10-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00973193",
      "title": "Preoperative Panitumumab and Radiotherapy in Rectal Cancer",
      "status": "TERMINATED",
      "last_update": "2016-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00975897",
      "title": "Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-12-19",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01001377",
      "title": "ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2022-09-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01030042",
      "title": "Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients",
      "status": "COMPLETED",
      "last_update": "2015-07-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01032291",
      "title": "A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2013-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01057017",
      "title": "First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras",
      "status": "TERMINATED",
      "last_update": "2020-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01060423",
      "title": "TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2016-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01086267",
      "title": "Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2016-06-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01108107",
      "title": "Neoadjuvant Treatment of Colon Cancer",
      "status": "COMPLETED",
      "last_update": "2015-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01110785",
      "title": "Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2013-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01126112",
      "title": "Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01139138",
      "title": "Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-11-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01144195",
      "title": "A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed \u2265 6 Months After the Last Dose of the First Line Chemotherapy",
      "status": "UNKNOWN",
      "last_update": "2010-11-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01161316",
      "title": "Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours",
      "status": "COMPLETED",
      "last_update": "2015-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01166035",
      "title": "Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2010-07-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01187901",
      "title": "A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients",
      "status": "COMPLETED",
      "last_update": "2016-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01198535",
      "title": "Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2015-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01212627",
      "title": "Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer",
      "status": "TERMINATED",
      "last_update": "2021-02-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01215539",
      "title": "Study of Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2015-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01226719",
      "title": "FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only",
      "status": "COMPLETED",
      "last_update": "2015-05-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01228734",
      "title": "A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients",
      "status": "COMPLETED",
      "last_update": "2020-01-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01251536",
      "title": "Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-10-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01254617",
      "title": "Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer",
      "status": "COMPLETED",
      "last_update": "2020-03-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01257360",
      "title": "Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)",
      "status": "UNKNOWN",
      "last_update": "2016-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01260415",
      "title": "A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases",
      "status": "COMPLETED",
      "last_update": "2019-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01285778",
      "title": "Vectibix for the Treatment of Anal Cancer",
      "status": "COMPLETED",
      "last_update": "2018-05-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01288339",
      "title": "Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2018-05-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01292356",
      "title": "Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response",
      "status": "COMPLETED",
      "last_update": "2017-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01312857",
      "title": "Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01315990",
      "title": "FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema",
      "status": "UNKNOWN",
      "last_update": "2013-12-18",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01322178",
      "title": "Study of Cetuximab in Combination With mFOLFOX-6 (Oxaliplatin, Leucovorin, 5-FU) to Treat Colorectal Liver Metastatic Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2011-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01328171",
      "title": "FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)",
      "status": "COMPLETED",
      "last_update": "2023-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01338558",
      "title": "A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Na\u00efve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab",
      "status": "WITHDRAWN",
      "last_update": "2016-11-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01345526",
      "title": "Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream",
      "status": "COMPLETED",
      "last_update": "2021-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01358812",
      "title": "FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-03-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01366118",
      "title": "Study of Therapeutic Targets Tailored Ch and IMRT as Neoadjuvant Treatment in Rectal Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2011-06-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01376505",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-09-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01384994",
      "title": "Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients",
      "status": "UNKNOWN",
      "last_update": "2012-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01412957",
      "title": "Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-03-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01418742",
      "title": "SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment",
      "status": "TERMINATED",
      "last_update": "2014-07-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01442649",
      "title": "Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab",
      "status": "COMPLETED",
      "last_update": "2022-01-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01442935",
      "title": "Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases",
      "status": "COMPLETED",
      "last_update": "2021-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01443377",
      "title": "Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01451632",
      "title": "A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2016-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01453257",
      "title": "Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients",
      "status": "COMPLETED",
      "last_update": "2011-10-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01504477",
      "title": "Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2020-03-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01508000",
      "title": "Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases",
      "status": "TERMINATED",
      "last_update": "2016-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01520389",
      "title": "Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment",
      "status": "COMPLETED",
      "last_update": "2018-03-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01564810",
      "title": "Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2012-10-24",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01591421",
      "title": "P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.",
      "status": "COMPLETED",
      "last_update": "2023-08-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01609231",
      "title": "A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)",
      "status": "TERMINATED",
      "last_update": "2020-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01637194",
      "title": "Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer",
      "status": "COMPLETED",
      "last_update": "2012-07-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01668498",
      "title": "Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2016-04-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01675999",
      "title": "Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer",
      "status": "UNKNOWN",
      "last_update": "2016-01-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01703910",
      "title": "Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic",
      "status": "COMPLETED",
      "last_update": "2015-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01704703",
      "title": "Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques",
      "status": "COMPLETED",
      "last_update": "2017-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01741038",
      "title": "AlloStim\u00ae In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2020-01-22",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01750918",
      "title": "BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)",
      "status": "COMPLETED",
      "last_update": "2021-10-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01776307",
      "title": "A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-11-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01791309",
      "title": "Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2016-01-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01801904",
      "title": "A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01802645",
      "title": "Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases",
      "status": "UNKNOWN",
      "last_update": "2019-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01814501",
      "title": "Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab",
      "status": "COMPLETED",
      "last_update": "2025-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01832467",
      "title": "Cetuximab Rechallenge Study",
      "status": "COMPLETED",
      "last_update": "2020-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01834014",
      "title": "Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases",
      "status": "COMPLETED",
      "last_update": "2017-08-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01862003",
      "title": "Phase I/II Trial of Antagonism of HER in GI Cancer",
      "status": "COMPLETED",
      "last_update": "2019-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01867697",
      "title": "Nordic 8 - A Phase II Trial",
      "status": "COMPLETED",
      "last_update": "2020-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01878422",
      "title": "Sequential Treatment Strategy for Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-01-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01892527",
      "title": "Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects",
      "status": "COMPLETED",
      "last_update": "2022-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01895257",
      "title": "Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2017-07-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01910610",
      "title": "Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-03-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01923987",
      "title": "Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis",
      "status": "UNKNOWN",
      "last_update": "2019-09-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01927341",
      "title": "Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors",
      "status": "COMPLETED",
      "last_update": "2021-02-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01960023",
      "title": "Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2021-10-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01991873",
      "title": "Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02008383",
      "title": "Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-02-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02015923",
      "title": "Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases",
      "status": "TERMINATED",
      "last_update": "2021-03-16",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02063529",
      "title": "FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2020-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02110082",
      "title": "Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer",
      "status": "COMPLETED",
      "last_update": "2017-04-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02162563",
      "title": "Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases",
      "status": "COMPLETED",
      "last_update": "2025-02-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02164916",
      "title": "S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2020-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02199223",
      "title": "Regorafenib + Panitumumab for Colorectal Cancers",
      "status": "TERMINATED",
      "last_update": "2016-09-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02205398",
      "title": "Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy",
      "status": "TERMINATED",
      "last_update": "2019-01-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02278133",
      "title": "Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations",
      "status": "COMPLETED",
      "last_update": "2017-10-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02292758",
      "title": "Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2022-01-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02301962",
      "title": "Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2019-12-16",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02314182",
      "title": "GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis",
      "status": "COMPLETED",
      "last_update": "2025-12-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02337946",
      "title": "Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-na\u00efve Unresectable Advanced Recurrent Colorectal Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02352571",
      "title": "Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer",
      "status": "UNKNOWN",
      "last_update": "2016-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02394795",
      "title": "Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC",
      "status": "COMPLETED",
      "last_update": "2023-11-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02399943",
      "title": "A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2022-05-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02442414",
      "title": "A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02448810",
      "title": "Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2021-05-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02476045",
      "title": "Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)",
      "status": "UNKNOWN",
      "last_update": "2016-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02484833",
      "title": "Erbitux MEtastatic Colorectal Cancer Strategy Study",
      "status": "COMPLETED",
      "last_update": "2020-03-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02508077",
      "title": "FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2018-08-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02538627",
      "title": "Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib",
      "status": "TERMINATED",
      "last_update": "2017-09-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02563002",
      "title": "Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)",
      "status": "COMPLETED",
      "last_update": "2024-10-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02568046",
      "title": "Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients",
      "status": "TERMINATED",
      "last_update": "2019-03-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02573220",
      "title": "Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2016-12-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02613221",
      "title": "A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-07-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02630420",
      "title": "Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2017-10-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02675946",
      "title": "CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)",
      "status": "UNKNOWN",
      "last_update": "2022-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02717923",
      "title": "A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2017-10-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02729298",
      "title": "First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-11-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02785068",
      "title": "Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2017-01-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02826837",
      "title": "LEAC-102 for Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2021-10-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02903914",
      "title": "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02904031",
      "title": "Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients",
      "status": "UNKNOWN",
      "last_update": "2020-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02934529",
      "title": "Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab",
      "status": "COMPLETED",
      "last_update": "2025-04-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02942706",
      "title": "Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC",
      "status": "UNKNOWN",
      "last_update": "2021-04-30",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02953782",
      "title": "Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-03-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02965417",
      "title": "Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients",
      "status": "WITHDRAWN",
      "last_update": "2017-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978313",
      "title": "Cetuximab Monotherapy Maintenance Treatment in mCRC",
      "status": "UNKNOWN",
      "last_update": "2016-11-30",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02980510",
      "title": "Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03000374",
      "title": "Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery",
      "status": "COMPLETED",
      "last_update": "2022-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03069950",
      "title": "Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver",
      "status": "WITHDRAWN",
      "last_update": "2019-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03087071",
      "title": "Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03135652",
      "title": "Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation",
      "status": "WITHDRAWN",
      "last_update": "2024-01-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03142516",
      "title": "FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status",
      "status": "COMPLETED",
      "last_update": "2021-06-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03146338",
      "title": "Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG)",
      "status": "UNKNOWN",
      "last_update": "2021-10-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03152435",
      "title": "EGFR CART Cells for Patients With Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2017-08-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03164655",
      "title": "Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network",
      "status": "COMPLETED",
      "last_update": "2024-10-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03167268",
      "title": "Panitumumab Skin Toxicity Prevention Trial",
      "status": "UNKNOWN",
      "last_update": "2021-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03169777",
      "title": "QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC",
      "status": "WITHDRAWN",
      "last_update": "2025-02-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03170960",
      "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03185988",
      "title": "Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System",
      "status": "UNKNOWN",
      "last_update": "2019-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03186326",
      "title": "Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2025-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03206151",
      "title": "CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-05-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03227926",
      "title": "Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance",
      "status": "COMPLETED",
      "last_update": "2022-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03231722",
      "title": "First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS",
      "status": "COMPLETED",
      "last_update": "2023-01-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03251612",
      "title": "Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03263429",
      "title": "Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-08-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03290937",
      "title": "Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-01-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03300609",
      "title": "5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab",
      "status": "TERMINATED",
      "last_update": "2020-06-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03311750",
      "title": "Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2021-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03319459",
      "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2021-11-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03365882",
      "title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2026-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03366155",
      "title": "Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver",
      "status": "COMPLETED",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03391934",
      "title": "Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux\u00ae (Merck) in Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-04-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03405272",
      "title": "Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC",
      "status": "UNKNOWN",
      "last_update": "2018-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03426371",
      "title": "Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial",
      "status": "TERMINATED",
      "last_update": "2026-05-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03428958",
      "title": "A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment",
      "status": "COMPLETED",
      "last_update": "2025-04-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03442569",
      "title": "PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC",
      "status": "COMPLETED",
      "last_update": "2025-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03448731",
      "title": "Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)",
      "status": "COMPLETED",
      "last_update": "2020-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03457896",
      "title": "Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status",
      "status": "UNKNOWN",
      "last_update": "2022-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03524820",
      "title": "Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2022-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03542799",
      "title": "EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-05-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03565003",
      "title": "A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China",
      "status": "COMPLETED",
      "last_update": "2024-09-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03567629",
      "title": "Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03584711",
      "title": "FOLFOX + Panitumumab According to a \"Stop and go\" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation",
      "status": "COMPLETED",
      "last_update": "2025-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03602079",
      "title": "Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene",
      "status": "COMPLETED",
      "last_update": "2023-08-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03635021",
      "title": "Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693807",
      "title": "A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma",
      "status": "COMPLETED",
      "last_update": "2026-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03698253",
      "title": "Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI",
      "status": "COMPLETED",
      "last_update": "2018-10-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03717038",
      "title": "Sym004 Versus TAS-102 in Patients With mCRC",
      "status": "WITHDRAWN",
      "last_update": "2019-02-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03751176",
      "title": "Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal",
      "status": "UNKNOWN",
      "last_update": "2021-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03764137",
      "title": "Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2025-01-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03803436",
      "title": "Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation",
      "status": "UNKNOWN",
      "last_update": "2023-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03803553",
      "title": "Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03811652",
      "title": "A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-12-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03875313",
      "title": "Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2022-02-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03919292",
      "title": "Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca",
      "status": "SUSPENDED",
      "last_update": "2026-06-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03940131",
      "title": "Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR",
      "status": "UNKNOWN",
      "last_update": "2022-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03944252",
      "title": "Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)",
      "status": "UNKNOWN",
      "last_update": "2019-07-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03983993",
      "title": "Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03992456",
      "title": "Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04034173",
      "title": "Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation",
      "status": "TERMINATED",
      "last_update": "2026-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04045496",
      "title": "A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04117945",
      "title": "Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04121286",
      "title": "A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China",
      "status": "COMPLETED",
      "last_update": "2025-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04160416",
      "title": "mXELOXIRI Combined With Molecular Targeted Drug in mCRC",
      "status": "UNKNOWN",
      "last_update": "2019-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04169347",
      "title": "FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04224415",
      "title": "Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC",
      "status": "COMPLETED",
      "last_update": "2023-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04276090",
      "title": "Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma",
      "status": "TERMINATED",
      "last_update": "2023-07-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04342676",
      "title": "Lymph Node Ratio and Kras Mutation in R Colon Cancer",
      "status": "COMPLETED",
      "last_update": "2020-04-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04425239",
      "title": "Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2022-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04464967",
      "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers",
      "status": "WITHDRAWN",
      "last_update": "2021-05-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04466254",
      "title": "Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2021-08-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04485013",
      "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04495621",
      "title": "MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)",
      "status": "COMPLETED",
      "last_update": "2025-05-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04509635",
      "title": "Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis",
      "status": "UNKNOWN",
      "last_update": "2020-08-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04513951",
      "title": "AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2025-01-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04515394",
      "title": "Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)",
      "status": "TERMINATED",
      "last_update": "2022-12-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04584008",
      "title": "Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04587128",
      "title": "Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04595266",
      "title": "Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04616183",
      "title": "LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04616196",
      "title": "Study of NKTR 255 in Combination With Cetuximab in Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04668976",
      "title": "A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-12-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04670679",
      "title": "A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04735900",
      "title": "lead-in FOLICOLOR Trial: Following Therapy Response Through Liquid Biopsy in Metastatic Colorectal Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2021-02-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04745130",
      "title": "Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)",
      "status": "UNKNOWN",
      "last_update": "2023-02-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04759664",
      "title": "LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC",
      "status": "UNKNOWN",
      "last_update": "2023-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04775862",
      "title": "A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.",
      "status": "UNKNOWN",
      "last_update": "2021-03-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04776655",
      "title": "Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04787341",
      "title": "PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence",
      "status": "COMPLETED",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04800822",
      "title": "PF-07284892 in Participants With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04833036",
      "title": "c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI",
      "status": "UNKNOWN",
      "last_update": "2021-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04835142",
      "title": "Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC",
      "status": "COMPLETED",
      "last_update": "2026-05-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04843033",
      "title": "A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2021-04-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04844073",
      "title": "A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer",
      "status": "TERMINATED",
      "last_update": "2025-12-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04853043",
      "title": "Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2025-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04878692",
      "title": "Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies",
      "status": "UNKNOWN",
      "last_update": "2021-05-07",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05004350",
      "title": "A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.",
      "status": "COMPLETED",
      "last_update": "2026-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05039177",
      "title": "A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-03-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05074966",
      "title": "The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts",
      "status": "UNKNOWN",
      "last_update": "2021-10-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05084859",
      "title": "A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-08-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05099549",
      "title": "Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers",
      "status": "TERMINATED",
      "last_update": "2024-03-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05121038",
      "title": "CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05143099",
      "title": "Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC",
      "status": "UNKNOWN",
      "last_update": "2023-03-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05160896",
      "title": "SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05162755",
      "title": "S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers",
      "status": "COMPLETED",
      "last_update": "2026-05-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05163028",
      "title": "A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05194995",
      "title": "JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05198934",
      "title": "Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation",
      "status": "COMPLETED",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05217069",
      "title": "FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC",
      "status": "COMPLETED",
      "last_update": "2025-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05239650",
      "title": "Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2022-05-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05239741",
      "title": "Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05278351",
      "title": "Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC",
      "status": "UNKNOWN",
      "last_update": "2023-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05308446",
      "title": "Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358249",
      "title": "Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05395052",
      "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05409417",
      "title": "Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status",
      "status": "UNKNOWN",
      "last_update": "2022-06-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05468892",
      "title": "Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial",
      "status": "COMPLETED",
      "last_update": "2024-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05497336",
      "title": "A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2026-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05510895",
      "title": "Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-10-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05540951",
      "title": "VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2022-09-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05576896",
      "title": "Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory",
      "status": "TERMINATED",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05578092",
      "title": "A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway",
      "status": "TERMINATED",
      "last_update": "2026-02-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05674526",
      "title": "A Phase 1b Study of WU-NK-101 in Combination With Cetuximab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-04-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05684211",
      "title": "A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05694936",
      "title": "Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05704985",
      "title": "Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05710406",
      "title": "Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05720559",
      "title": "Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection",
      "status": "UNKNOWN",
      "last_update": "2023-02-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05743036",
      "title": "ZN-c3 in Adult Participants With Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2025-08-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05797883",
      "title": "FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu \u00ae) in the Treatment of Unresectable or Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05862051",
      "title": "RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05873972",
      "title": "Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient",
      "status": "UNKNOWN",
      "last_update": "2023-05-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06011772",
      "title": "EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06022276",
      "title": "Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-09-01",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06035133",
      "title": "Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-09-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06147037",
      "title": "A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06194877",
      "title": "A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers",
      "status": "TERMINATED",
      "last_update": "2025-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06231017",
      "title": "Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06268015",
      "title": "Botensilimab and Balstilimab Optimization in Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06332079",
      "title": "Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients",
      "status": "TERMINATED",
      "last_update": "2026-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06358430",
      "title": "Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06501989",
      "title": "Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2026-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06575127",
      "title": "Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study",
      "status": "UNKNOWN",
      "last_update": "2024-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06578559",
      "title": "Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06681038",
      "title": "Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06704724",
      "title": "A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.",
      "status": "TERMINATED",
      "last_update": "2026-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06908031",
      "title": "SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06959589",
      "title": "The Efficacy and Safety of IBI351, Cetuximab \u03b2 Combined With FOLFIRI as First-line /IBI351, Cetuximab \u03b2 as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06967155",
      "title": "A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07059338",
      "title": "Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07070713",
      "title": "Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07079462",
      "title": "Comparing 18F-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07094893",
      "title": "Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07124884",
      "title": "5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07178717",
      "title": "A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07209384",
      "title": "Clinical Efficacy of Transarterial Chemoembolization in Elderly Patients With Advanced Unresectable Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-10-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07297433",
      "title": "Erector Spinae Plane Block in Laparoscopic Colorectal Cancer Surgery",
      "status": "COMPLETED",
      "last_update": "2026-05-27",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07318389",
      "title": "ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07446270",
      "title": "Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07490119",
      "title": "Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07503639",
      "title": "Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07509398",
      "title": "FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-03",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07515963",
      "title": "FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07551778",
      "title": "Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07621497",
      "title": "FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07649655",
      "title": "EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07683403",
      "title": "Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07691489",
      "title": "A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07807956",
      "title": "A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07811453",
      "title": "Liver Transplantation for Non-Resectable Colorectal Liver Metastases Without Local Treatment Options",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 7,
     "n_observational": 0,
     "n_active": 4,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT04842812",
       "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2024-06-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06682793",
       "title": "A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression",
       "status": "RECRUITING",
       "last_update": "2025-09-09",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03152435",
       "title": "EGFR CART Cells for Patients With Metastatic Colorectal Cancer",
       "status": "UNKNOWN",
       "last_update": "2017-08-16",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03542799",
       "title": "EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer",
       "status": "UNKNOWN",
       "last_update": "2018-05-31",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04616196",
       "title": "Study of NKTR 255 in Combination With Cetuximab in Solid Tumors",
       "status": "COMPLETED",
       "last_update": "2025-06-08",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06358430",
       "title": "Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-08-04",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07551778",
       "title": "Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "EGFR",
     "cetuximab",
     "panitumumab"
    ]
   },
   "PD-1": {
    "n": 449,
    "n_observational": 24,
    "n_active": 220,
    "n_withdrawn": 19,
    "trials": [
     {
      "nct": "NCT01174121",
      "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03026140",
      "title": "Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer",
      "status": "RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03526835",
      "title": "A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03755739",
      "title": "Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-06-25",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03926338",
      "title": "Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-11-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04014530",
      "title": "Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study",
      "status": "RECRUITING",
      "last_update": "2023-02-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04109755",
      "title": "Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2021-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04165772",
      "title": "Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04282044",
      "title": "Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies",
      "status": "RECRUITING",
      "last_update": "2024-02-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04429542",
      "title": "Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04585750",
      "title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04701476",
      "title": "TATE and Pembrolizumab (MK3475) in mCRC and NSCLC",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04842812",
      "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04895709",
      "title": "A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04912765",
      "title": "Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC",
      "status": "RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04991948",
      "title": "Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2022-03-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05024097",
      "title": "A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05086692",
      "title": "A Beta-only IL-2 ImmunoTherapY Study",
      "status": "RECRUITING",
      "last_update": "2025-07-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05176483",
      "title": "Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05187338",
      "title": "Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-06-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05239546",
      "title": "Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers",
      "status": "RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05310643",
      "title": "Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC",
      "status": "RECRUITING",
      "last_update": "2025-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05450029",
      "title": "Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2023-09-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05462236",
      "title": "MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05492682",
      "title": "START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05628038",
      "title": "The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-10-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05669430",
      "title": "A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-02-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05719558",
      "title": "A Study of ASP1002 in Adults for Treatment of Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05725200",
      "title": "Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2023-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05731726",
      "title": "Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05732389",
      "title": "Immunotherapy in Patients With Early dMMR Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05746897",
      "title": "A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05768503",
      "title": "Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC",
      "status": "RECRUITING",
      "last_update": "2023-03-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05784688",
      "title": "Study of TU2218 in Combination With KEYTRUDA\u00ae(Pembrolizumab) in Patients With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-03-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05824975",
      "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)",
      "status": "RECRUITING",
      "last_update": "2024-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05845450",
      "title": "Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05855200",
      "title": "Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer",
      "status": "RECRUITING",
      "last_update": "2026-01-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05856981",
      "title": "Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-12-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05919264",
      "title": "FOG-001 in Locally Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05944237",
      "title": "HTL0039732 in Participants With Advanced Solid Tumours",
      "status": "RECRUITING",
      "last_update": "2025-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06002789",
      "title": "Safety and Efficacy of PD-1 \u00b1 mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC",
      "status": "RECRUITING",
      "last_update": "2026-04-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06205836",
      "title": "Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06245356",
      "title": "Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-12-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06253871",
      "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06254521",
      "title": "The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06265025",
      "title": "GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-03-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06265285",
      "title": "Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",
      "status": "RECRUITING",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06270706",
      "title": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06333314",
      "title": "Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI",
      "status": "RECRUITING",
      "last_update": "2025-12-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06362369",
      "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06400472",
      "title": "A Study of Sofe-M in Participants With Selected Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06428409",
      "title": "A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06455124",
      "title": "Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)",
      "status": "RECRUITING",
      "last_update": "2024-06-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06490536",
      "title": "The Sagittarius Trial",
      "status": "RECRUITING",
      "last_update": "2025-08-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06493019",
      "title": "Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06520683",
      "title": "Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-11-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06522919",
      "title": "Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06529523",
      "title": "Tislelizumab in People With Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06530303",
      "title": "Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer",
      "status": "RECRUITING",
      "last_update": "2024-11-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06542588",
      "title": "Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC",
      "status": "RECRUITING",
      "last_update": "2024-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06555003",
      "title": "DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases",
      "status": "RECRUITING",
      "last_update": "2025-04-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06567782",
      "title": "A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06590259",
      "title": "A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM",
      "status": "RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06634875",
      "title": "Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)",
      "status": "RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06638931",
      "title": "Agnostic Therapy in Rare Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06751914",
      "title": "Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment",
      "status": "RECRUITING",
      "last_update": "2024-12-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06764771",
      "title": "A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06789172",
      "title": "A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06791512",
      "title": "mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC",
      "status": "RECRUITING",
      "last_update": "2025-12-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06830239",
      "title": "Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer",
      "status": "RECRUITING",
      "last_update": "2026-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06835569",
      "title": "A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations",
      "status": "RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06841159",
      "title": "Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1\uff0cChemotherapy and Target Therapy for Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-02-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06846268",
      "title": "Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-07-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06856837",
      "title": "- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases",
      "status": "RECRUITING",
      "last_update": "2025-12-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06889610",
      "title": "A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06903858",
      "title": "Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06917079",
      "title": "BBO-11818 in Adult Subjects With KRAS Mutant Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06923345",
      "title": "Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)",
      "status": "RECRUITING",
      "last_update": "2025-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06943820",
      "title": "AK129 Combination Therapy for Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-06-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06948448",
      "title": "A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo\u00ae, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06983743",
      "title": "A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07020221",
      "title": "A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07068763",
      "title": "Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07094113",
      "title": "AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07223047",
      "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07223424",
      "title": "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07244705",
      "title": "A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC",
      "status": "RECRUITING",
      "last_update": "2025-11-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07255664",
      "title": "A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC",
      "status": "RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07262619",
      "title": "EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07281768",
      "title": "Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07328087",
      "title": "COLONYVAQ\u2122, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-01-09",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07334119",
      "title": "Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07353645",
      "title": "KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07365592",
      "title": "Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC",
      "status": "RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07376707",
      "title": "A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07410676",
      "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-02-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07412613",
      "title": "Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07448142",
      "title": "Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07458529",
      "title": "Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07468630",
      "title": "Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma",
      "status": "RECRUITING",
      "last_update": "2026-03-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07503756",
      "title": "JS212 Combination Therapies in Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07527858",
      "title": "Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07549399",
      "title": "SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC",
      "status": "RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07646639",
      "title": "Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC",
      "status": "RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07687875",
      "title": "Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07692152",
      "title": "Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-07-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07749586",
      "title": "A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00441337",
      "title": "A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies",
      "status": "COMPLETED",
      "last_update": "2015-02-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01876511",
      "title": "Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)",
      "status": "COMPLETED",
      "last_update": "2020-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02009449",
      "title": "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02060188",
      "title": "A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread",
      "status": "COMPLETED",
      "last_update": "2025-11-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02178722",
      "title": "Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers",
      "status": "COMPLETED",
      "last_update": "2022-02-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02260440",
      "title": "A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02268825",
      "title": "Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers",
      "status": "TERMINATED",
      "last_update": "2018-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02298946",
      "title": "AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-02-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02298959",
      "title": "Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02314169",
      "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02318901",
      "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer",
      "status": "TERMINATED",
      "last_update": "2019-10-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02327078",
      "title": "A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02335918",
      "title": "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-12-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02346955",
      "title": "Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)",
      "status": "TERMINATED",
      "last_update": "2020-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02359565",
      "title": "Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02375672",
      "title": "Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2022-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02408861",
      "title": "Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2026-01-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02423954",
      "title": "Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)",
      "status": "TERMINATED",
      "last_update": "2018-07-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02437071",
      "title": "Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2025-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02460198",
      "title": "Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)",
      "status": "COMPLETED",
      "last_update": "2023-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02512172",
      "title": "A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-12-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02563002",
      "title": "Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)",
      "status": "COMPLETED",
      "last_update": "2024-10-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02586610",
      "title": "Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2017-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02599324",
      "title": "Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors",
      "status": "COMPLETED",
      "last_update": "2023-11-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02600949",
      "title": "Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-06-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02628067",
      "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02635672",
      "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2024-11-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02636036",
      "title": "Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors",
      "status": "COMPLETED",
      "last_update": "2021-11-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02646748",
      "title": "Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-03-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02675946",
      "title": "CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)",
      "status": "UNKNOWN",
      "last_update": "2022-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02713373",
      "title": "Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2022-10-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02757391",
      "title": "CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors",
      "status": "TERMINATED",
      "last_update": "2020-10-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02817633",
      "title": "A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02834013",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02834052",
      "title": "Pembrolizumab + Poly-ICLC in MRP Colon Cancer",
      "status": "COMPLETED",
      "last_update": "2024-06-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02837263",
      "title": "PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02842125",
      "title": "Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer",
      "status": "TERMINATED",
      "last_update": "2020-06-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02848443",
      "title": "Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-07-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02851004",
      "title": "Special Combination of BBI608 and Pembrolizumab",
      "status": "TERMINATED",
      "last_update": "2021-09-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02860546",
      "title": "A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC",
      "status": "COMPLETED",
      "last_update": "2024-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890069",
      "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",
      "status": "COMPLETED",
      "last_update": "2023-01-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02903914",
      "title": "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02919969",
      "title": "Pembrolizumab in Metastatic Anal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02921256",
      "title": "Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-12-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02933944",
      "title": "Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2022-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02948348",
      "title": "Study to Nivolumab Following Preoperative Chemoradiotherapy",
      "status": "UNKNOWN",
      "last_update": "2021-09-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02952989",
      "title": "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2019-07-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02959437",
      "title": "Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)",
      "status": "TERMINATED",
      "last_update": "2025-10-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02972034",
      "title": "Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)",
      "status": "TERMINATED",
      "last_update": "2024-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978625",
      "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02981524",
      "title": "Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02983045",
      "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02991196",
      "title": "Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2019-02-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03009058",
      "title": "Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer",
      "status": "TERMINATED",
      "last_update": "2024-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03058289",
      "title": "A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6",
      "status": "COMPLETED",
      "last_update": "2025-02-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03085914",
      "title": "A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)",
      "status": "COMPLETED",
      "last_update": "2022-09-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03104439",
      "title": "Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126110",
      "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03169777",
      "title": "QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC",
      "status": "WITHDRAWN",
      "last_update": "2025-02-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03170960",
      "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03182894",
      "title": "Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2018-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03184870",
      "title": "A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-10-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03190174",
      "title": "Nivolumab (Opdivo\u00ae) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers",
      "status": "COMPLETED",
      "last_update": "2025-02-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03228667",
      "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03233711",
      "title": "Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03239145",
      "title": "Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor",
      "status": "COMPLETED",
      "last_update": "2026-07-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03250832",
      "title": "Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-04-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03251612",
      "title": "Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03271047",
      "title": "Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation",
      "status": "COMPLETED",
      "last_update": "2022-01-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03274804",
      "title": "Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC",
      "status": "COMPLETED",
      "last_update": "2022-06-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03307603",
      "title": "Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2018-02-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03329950",
      "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-03-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03332498",
      "title": "Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers",
      "status": "COMPLETED",
      "last_update": "2022-06-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03350126",
      "title": "iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03361228",
      "title": "A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2020-05-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03373188",
      "title": "VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03374254",
      "title": "Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)",
      "status": "COMPLETED",
      "last_update": "2024-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03377361",
      "title": "An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread",
      "status": "COMPLETED",
      "last_update": "2025-12-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03388190",
      "title": "METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin",
      "status": "COMPLETED",
      "last_update": "2026-02-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03396926",
      "title": "Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-02-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03414983",
      "title": "An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread",
      "status": "COMPLETED",
      "last_update": "2023-11-18",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03435640",
      "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies",
      "status": "TERMINATED",
      "last_update": "2023-03-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03442569",
      "title": "PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC",
      "status": "COMPLETED",
      "last_update": "2025-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03454451",
      "title": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2023-12-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03473925",
      "title": "Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)",
      "status": "COMPLETED",
      "last_update": "2024-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03475004",
      "title": "Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03485209",
      "title": "Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03507699",
      "title": "Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-04-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03519412",
      "title": "Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status",
      "status": "COMPLETED",
      "last_update": "2026-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03547999",
      "title": "A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC",
      "status": "TERMINATED",
      "last_update": "2025-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03549000",
      "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.",
      "status": "TERMINATED",
      "last_update": "2024-12-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03576963",
      "title": "Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2021-04-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03621982",
      "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-06-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03626922",
      "title": "Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2022-06-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03629756",
      "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-05-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03631407",
      "title": "Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)",
      "status": "COMPLETED",
      "last_update": "2024-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03631641",
      "title": "Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy",
      "status": "TERMINATED",
      "last_update": "2024-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03638297",
      "title": "PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-10-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03639714",
      "title": "A Study of a Personalized Neoantigen Cancer Vaccine",
      "status": "COMPLETED",
      "last_update": "2023-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03642067",
      "title": "Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03645876",
      "title": "SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2019-05-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03647839",
      "title": "Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03657641",
      "title": "Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03658772",
      "title": "Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-10-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03667716",
      "title": "COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.",
      "status": "COMPLETED",
      "last_update": "2025-01-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693846",
      "title": "Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors",
      "status": "TERMINATED",
      "last_update": "2022-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03711058",
      "title": "Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-09-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03712943",
      "title": "Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-02-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03724851",
      "title": "Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer",
      "status": "COMPLETED",
      "last_update": "2025-03-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03761914",
      "title": "Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2024-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03775850",
      "title": "A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03785210",
      "title": "Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers",
      "status": "TERMINATED",
      "last_update": "2026-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03785249",
      "title": "Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03791398",
      "title": "BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC",
      "status": "TERMINATED",
      "last_update": "2023-02-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03797326",
      "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)",
      "status": "COMPLETED",
      "last_update": "2026-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03799003",
      "title": "A Study of ASP1951 in Subjects With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-11-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03800602",
      "title": "Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03803553",
      "title": "Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03811652",
      "title": "A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-12-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03829436",
      "title": "TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2023-07-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03832621",
      "title": "NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2022-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03841110",
      "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03867799",
      "title": "iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-06-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03871959",
      "title": "Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma",
      "status": "COMPLETED",
      "last_update": "2023-02-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03872947",
      "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03879811",
      "title": "Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2025-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03904537",
      "title": "A Study of Combination of Anti-PD1 Antibody-activated TILs and Chemotherapy in Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2019-04-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03921684",
      "title": "Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03948763",
      "title": "A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)",
      "status": "TERMINATED",
      "last_update": "2025-01-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03950154",
      "title": "Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-08-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03953235",
      "title": "A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens",
      "status": "COMPLETED",
      "last_update": "2023-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03970382",
      "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors",
      "status": "SUSPENDED",
      "last_update": "2022-08-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03981146",
      "title": "A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03982121",
      "title": "Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy",
      "status": "WITHDRAWN",
      "last_update": "2020-02-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03984578",
      "title": "Window of Opportunity Study in Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03993626",
      "title": "A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2019-06-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04000529",
      "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04001101",
      "title": "Anti-PD-1 +/- RT for MSI-H Solid Tumors",
      "status": "WITHDRAWN",
      "last_update": "2021-11-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04008030",
      "title": "A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04017650",
      "title": "Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04044430",
      "title": "Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2023-01-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04046133",
      "title": "Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04060342",
      "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma",
      "status": "TERMINATED",
      "last_update": "2022-08-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04072198",
      "title": "Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients",
      "status": "COMPLETED",
      "last_update": "2025-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04083599",
      "title": "GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04110093",
      "title": "Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2020-12-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04117087",
      "title": "Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04118933",
      "title": "A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2019-10-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04119830",
      "title": "Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2022-02-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04124601",
      "title": "Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04126733",
      "title": "Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)",
      "status": "COMPLETED",
      "last_update": "2023-07-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04140526",
      "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04166383",
      "title": "VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)",
      "status": "TERMINATED",
      "last_update": "2026-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04194359",
      "title": "Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04195373",
      "title": "A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract",
      "status": "WITHDRAWN",
      "last_update": "2020-11-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04208958",
      "title": "Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2025-10-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04231526",
      "title": "Pembrolizumab in Early Stage Colon Cancer",
      "status": "WITHDRAWN",
      "last_update": "2024-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04231552",
      "title": "Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2020-11-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04244552",
      "title": "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies",
      "status": "TERMINATED",
      "last_update": "2023-12-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04256707",
      "title": "Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment",
      "status": "COMPLETED",
      "last_update": "2025-03-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04262687",
      "title": "Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate",
      "status": "UNKNOWN",
      "last_update": "2023-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04272034",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-10-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04278144",
      "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-09-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04301011",
      "title": "Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04301557",
      "title": "PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04304209",
      "title": "Pd1 Antibody Sintilimab \u00b1 Chemoradiotherapy for Locally Advanced Rectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2023-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04306900",
      "title": "TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2025-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04332653",
      "title": "NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-03-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04344795",
      "title": "Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-09-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04354246",
      "title": "COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04357873",
      "title": "Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations",
      "status": "COMPLETED",
      "last_update": "2025-02-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04362839",
      "title": "Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-01-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04430738",
      "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04430985",
      "title": "FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2021-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04432857",
      "title": "AN0025 and Pembrolizumab Combination in Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-06-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04444921",
      "title": "EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04446091",
      "title": "A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)",
      "status": "UNKNOWN",
      "last_update": "2020-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04457284",
      "title": "Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04460456",
      "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2022-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04485013",
      "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04500548",
      "title": "Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study",
      "status": "WITHDRAWN",
      "last_update": "2026-06-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04503694",
      "title": "Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04503980",
      "title": "\u03b1PD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2020-08-07",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04508140",
      "title": "Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis",
      "status": "TERMINATED",
      "last_update": "2024-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04527068",
      "title": "QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2020-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04556253",
      "title": "AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04558684",
      "title": "Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer",
      "status": "SUSPENDED",
      "last_update": "2024-01-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04575922",
      "title": "Nivolumab+Ipilimumab+RT in MSS mCRC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2022-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04599140",
      "title": "SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04606472",
      "title": "A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04609579",
      "title": "Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-01-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04660812",
      "title": "An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.",
      "status": "COMPLETED",
      "last_update": "2025-10-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04660929",
      "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04670679",
      "title": "A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04682431",
      "title": "A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-03-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04699188",
      "title": "Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04708470",
      "title": "A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04711434",
      "title": "PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients",
      "status": "UNKNOWN",
      "last_update": "2021-01-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04715633",
      "title": "PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04721301",
      "title": "Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial",
      "status": "COMPLETED",
      "last_update": "2023-10-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04729322",
      "title": "Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04730544",
      "title": "Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-06-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04731467",
      "title": "A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-12-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04751370",
      "title": "Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04764006",
      "title": "Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study",
      "status": "UNKNOWN",
      "last_update": "2021-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04802876",
      "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04854434",
      "title": "A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations",
      "status": "TERMINATED",
      "last_update": "2023-11-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04895137",
      "title": "mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC",
      "status": "COMPLETED",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04895722",
      "title": "Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04907539",
      "title": "A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)",
      "status": "COMPLETED",
      "last_update": "2025-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04911517",
      "title": "Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.",
      "status": "UNKNOWN",
      "last_update": "2022-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913337",
      "title": "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies",
      "status": "UNKNOWN",
      "last_update": "2024-10-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04926324",
      "title": "A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers",
      "status": "TERMINATED",
      "last_update": "2026-06-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04929028",
      "title": "Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04940546",
      "title": "Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04943900",
      "title": "A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-04-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04952753",
      "title": "Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC",
      "status": "TERMINATED",
      "last_update": "2025-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04956640",
      "title": "Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04963283",
      "title": "Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05035381",
      "title": "PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2021-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05061017",
      "title": "Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)",
      "status": "COMPLETED",
      "last_update": "2026-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05061537",
      "title": "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-04-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05064059",
      "title": "A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)",
      "status": "COMPLETED",
      "last_update": "2026-05-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05068206",
      "title": "A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx",
      "status": "UNKNOWN",
      "last_update": "2021-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05131919",
      "title": "Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05143099",
      "title": "Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC",
      "status": "UNKNOWN",
      "last_update": "2023-03-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05162755",
      "title": "S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers",
      "status": "COMPLETED",
      "last_update": "2026-05-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05167409",
      "title": "Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05201612",
      "title": "Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).",
      "status": "UNKNOWN",
      "last_update": "2023-02-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05215574",
      "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05217446",
      "title": "A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05239741",
      "title": "Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05256381",
      "title": "A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05277051",
      "title": "First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05278351",
      "title": "Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC",
      "status": "UNKNOWN",
      "last_update": "2023-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05308446",
      "title": "Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05311618",
      "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05328908",
      "title": "A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2026-08-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05333809",
      "title": "Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2022-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05350501",
      "title": "EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2025-09-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05359393",
      "title": "A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2022-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05374252",
      "title": "Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients",
      "status": "UNKNOWN",
      "last_update": "2022-05-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05395052",
      "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05446129",
      "title": "A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery",
      "status": "TERMINATED",
      "last_update": "2025-03-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05484024",
      "title": "Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2022-08-02",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05504252",
      "title": "METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05507112",
      "title": "TIME in Immunotherapy Combined With nCRT for Rectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05518032",
      "title": "Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)",
      "status": "WITHDRAWN",
      "last_update": "2024-09-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05571293",
      "title": "Combination Immunotherapy in Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05576077",
      "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05581004",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05582031",
      "title": "Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers",
      "status": "WITHDRAWN",
      "last_update": "2023-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05585034",
      "title": "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb\u00ae808 in Combination With Pembrolizumab in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-08-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05588297",
      "title": "Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases",
      "status": "UNKNOWN",
      "last_update": "2022-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05589597",
      "title": "EO4010 in Previously Treated Metastatic Colorectal Carcinoma",
      "status": "TERMINATED",
      "last_update": "2025-08-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05608044",
      "title": "A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05609656",
      "title": "Electroporation and Immunotherapy in Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2024-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620134",
      "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05640726",
      "title": "The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy",
      "status": "UNKNOWN",
      "last_update": "2022-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05662527",
      "title": "Response to Immunotherapy in MMR-deficient Localized Colon Cancer",
      "status": "COMPLETED",
      "last_update": "2024-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05690035",
      "title": "Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2024-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05704985",
      "title": "Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05708950",
      "title": "A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)",
      "status": "COMPLETED",
      "last_update": "2026-06-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05714553",
      "title": "NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours",
      "status": "TERMINATED",
      "last_update": "2026-07-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05723562",
      "title": "A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05747716",
      "title": "SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-02-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05787587",
      "title": "A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05792735",
      "title": "Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05838768",
      "title": "Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05858736",
      "title": "Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05860374",
      "title": "A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-05-16",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05872867",
      "title": "Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)",
      "status": "UNKNOWN",
      "last_update": "2024-03-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05909423",
      "title": "Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05957016",
      "title": "Neoadjuvant CIETAI With Concurrent Chemoradiotherapy in Local Advanced Rectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-08-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06006923",
      "title": "Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2026-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06014944",
      "title": "Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06017583",
      "title": "Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-10-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047015",
      "title": "Irreversible Electroporation (NanoKnife \u00ae) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-08-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06084689",
      "title": "Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures",
      "status": "WITHDRAWN",
      "last_update": "2025-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06131398",
      "title": "A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-08-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06206096",
      "title": "PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC",
      "status": "UNKNOWN",
      "last_update": "2024-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06285097",
      "title": "A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-09-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06301386",
      "title": "Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06365970",
      "title": "Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers",
      "status": "WITHDRAWN",
      "last_update": "2025-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06394791",
      "title": "Evaluation of The Efficacy And Safety of PD-1 + IL-2 Combined With Capox Treatment After Loop Colostomy Surgery in Left-sided Colorectal Cancer Patients Complicating Acute Obstruction",
      "status": "UNKNOWN",
      "last_update": "2024-05-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06400160",
      "title": "Clinical Trial of TB511 in Advanced Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06410534",
      "title": "A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2025-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06415851",
      "title": "Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab",
      "status": "UNKNOWN",
      "last_update": "2024-05-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06447662",
      "title": "A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06448364",
      "title": "A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination",
      "status": "TERMINATED",
      "last_update": "2024-11-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06540261",
      "title": "The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06543836",
      "title": "ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-08-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06544655",
      "title": "A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06546553",
      "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.",
      "status": "TERMINATED",
      "last_update": "2026-02-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06547385",
      "title": "Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-08-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06550453",
      "title": "Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-11-12",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06599827",
      "title": "Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06640049",
      "title": "A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06646445",
      "title": "Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06692959",
      "title": "A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2026-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06699836",
      "title": "CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06704724",
      "title": "A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.",
      "status": "TERMINATED",
      "last_update": "2026-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06710847",
      "title": "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06823323",
      "title": "The Study on the Efficacy and Safety of Lactobacillus Johnsonii in Combination with CapeOX and Pembrolizumab for the Treatment of MSS/pMMR Metastatic Colorectal Cancer.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-02-12",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06865521",
      "title": "Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06884670",
      "title": "Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study",
      "status": "COMPLETED",
      "last_update": "2026-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06908031",
      "title": "SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07007767",
      "title": "Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies\uff09",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07011550",
      "title": "Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer",
      "status": "SUSPENDED",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07031011",
      "title": "PD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07132008",
      "title": "Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07132463",
      "title": "Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07175636",
      "title": "QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07403877",
      "title": "Neoadjuvant Immunotherapy \u00b1 Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07409844",
      "title": "Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07411781",
      "title": "PIN in Combination With Sintilimab in Previously Treated pMMR/MSS CRC With Hepatic Metastases",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07486492",
      "title": "Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-20",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07502014",
      "title": "A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07523763",
      "title": "Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07535632",
      "title": "SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07542262",
      "title": "Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07543848",
      "title": "A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07576725",
      "title": "Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07591597",
      "title": "A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07620574",
      "title": "Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07623642",
      "title": "A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07656766",
      "title": "Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07680088",
      "title": "Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07737600",
      "title": "A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07740720",
      "title": "A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07750158",
      "title": "Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07755124",
      "title": "Dietary Arginine Deprivation Combined With Chemoradiotherapy for Neoadjuvant Treatment of Rectal Cancer: A Randomized Controlled Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07765667",
      "title": "NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07779694",
      "title": "16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07807345",
      "title": "Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07808151",
      "title": "Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07811193",
      "title": "A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 10,
     "n_observational": 0,
     "n_active": 5,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT01174121",
       "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer",
       "status": "RECRUITING",
       "last_update": "2026-09-01",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04842812",
       "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2024-06-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06530303",
       "title": "Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer",
       "status": "RECRUITING",
       "last_update": "2024-11-05",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07410676",
       "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2026-02-18",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02757391",
       "title": "CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors",
       "status": "TERMINATED",
       "last_update": "2020-10-30",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02983045",
       "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
       "status": "COMPLETED",
       "last_update": "2023-03-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03435640",
       "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies",
       "status": "TERMINATED",
       "last_update": "2023-03-08",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03970382",
       "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors",
       "status": "SUSPENDED",
       "last_update": "2022-08-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04503980",
       "title": "\u03b1PD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors",
       "status": "UNKNOWN",
       "last_update": "2020-08-07",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07031011",
       "title": "PD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal Cancer",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2025-06-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "PD-1",
     "pembrolizumab",
     "nivolumab",
     "dostarlimab"
    ]
   },
   "CLDN18.2": {
    "n": 3,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07488676",
      "title": "A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05937919",
      "title": "68Ga-PMD22 PET/CT Examination Targeting CLDN18.2",
      "status": "UNKNOWN",
      "last_update": "2023-07-10",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06792435",
      "title": "XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "CLDN18.2",
     "claudin 18.2",
     "zolbetuximab"
    ]
   },
   "TROP2": {
    "n": 11,
    "n_observational": 0,
    "n_active": 11,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05489211",
      "title": "Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05941507",
      "title": "A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-09-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05969041",
      "title": "Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors",
      "status": "RECRUITING",
      "last_update": "2024-01-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06065371",
      "title": "Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy",
      "status": "RECRUITING",
      "last_update": "2025-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06243393",
      "title": "Sacituzumab Govitecan in Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-07-10",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06428409",
      "title": "A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06715839",
      "title": "Target-specific immunoPET Imaging of Digestive System Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-12-31",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06889610",
      "title": "A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07026110",
      "title": "Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer",
      "status": "RECRUITING",
      "last_update": "2025-06-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07411599",
      "title": "Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial (\"Chip-CRC Trial\")",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06358430",
      "title": "Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT06358430",
       "title": "Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-08-04",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "TROP2",
     "TROP-2",
     "TACSTD2",
     "sacituzumab"
    ]
   },
   "LGR5": {
    "n": 3,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03526835",
      "title": "A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05759728",
      "title": "A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-01-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02726334",
      "title": "A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.",
      "status": "TERMINATED",
      "last_update": "2019-01-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT05759728",
       "title": "A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer",
       "status": "RECRUITING",
       "last_update": "2026-01-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "LGR5"
    ]
   },
   "MUC1": {
    "n": 19,
    "n_observational": 0,
    "n_active": 6,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT04842812",
      "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06149481",
      "title": "Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00088413",
      "title": "PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2019-04-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00103142",
      "title": "Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-10-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00773097",
      "title": "Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma",
      "status": "COMPLETED",
      "last_update": "2019-01-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01462513",
      "title": "L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases",
      "status": "COMPLETED",
      "last_update": "2018-02-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02134925",
      "title": "Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02617134",
      "title": "CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor",
      "status": "UNKNOWN",
      "last_update": "2016-12-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02839954",
      "title": "CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor",
      "status": "UNKNOWN",
      "last_update": "2016-12-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03169777",
      "title": "QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC",
      "status": "WITHDRAWN",
      "last_update": "2025-02-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03384316",
      "title": "Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2020-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03524274",
      "title": "Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2020-10-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03563157",
      "title": "QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine",
      "status": "TERMINATED",
      "last_update": "2024-12-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03642067",
      "title": "Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04491955",
      "title": "Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers",
      "status": "COMPLETED",
      "last_update": "2025-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05239143",
      "title": "P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05419011",
      "title": "Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06010901",
      "title": "A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection \u00b1Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.",
      "status": "UNKNOWN",
      "last_update": "2024-01-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07670312",
      "title": "Evaluation of XYA02 in Patients With Advanced Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 4,
     "n_observational": 0,
     "n_active": 2,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT04842812",
       "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2024-06-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02617134",
       "title": "CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor",
       "status": "UNKNOWN",
       "last_update": "2016-12-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02839954",
       "title": "CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor",
       "status": "UNKNOWN",
       "last_update": "2016-12-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05239143",
       "title": "P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-02-09",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "MUC1",
     "mucin-1"
    ]
   },
   "NKG2D": {
    "n": 10,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT03692429",
      "title": "alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells",
      "status": "RECRUITING",
      "last_update": "2020-11-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04991948",
      "title": "Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2022-03-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03310008",
      "title": "Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases",
      "status": "UNKNOWN",
      "last_update": "2020-06-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03370198",
      "title": "Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2024-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04107142",
      "title": "Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted \u03b3\u03b4 T Cells for Relapsed or Refractory Solid Tumour",
      "status": "UNKNOWN",
      "last_update": "2019-09-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04270461",
      "title": "NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors",
      "status": "WITHDRAWN",
      "last_update": "2020-10-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04550663",
      "title": "NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors",
      "status": "UNKNOWN",
      "last_update": "2020-09-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05131763",
      "title": "NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2021-11-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05213195",
      "title": "NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-02-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05248048",
      "title": "NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2022-02-21",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 7,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 1,
     "trials": [
      {
       "nct": "NCT03692429",
       "title": "alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells",
       "status": "RECRUITING",
       "last_update": "2020-11-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04107142",
       "title": "Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted \u03b3\u03b4 T Cells for Relapsed or Refractory Solid Tumour",
       "status": "UNKNOWN",
       "last_update": "2019-09-27",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04270461",
       "title": "NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors",
       "status": "WITHDRAWN",
       "last_update": "2020-10-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04550663",
       "title": "NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors",
       "status": "UNKNOWN",
       "last_update": "2020-09-23",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05131763",
       "title": "NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors",
       "status": "UNKNOWN",
       "last_update": "2021-11-23",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05213195",
       "title": "NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer",
       "status": "UNKNOWN",
       "last_update": "2024-02-12",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05248048",
       "title": "NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer",
       "status": "UNKNOWN",
       "last_update": "2022-02-21",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "NKG2D",
     "NKG2D ligand",
     "CYAD-101"
    ]
   }
  },
  "by_drug": {
   "ADAGRASIB": {
    "n": 12,
    "n_observational": 0,
    "n_active": 7,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06026410",
      "title": "KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06412198",
      "title": "A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations",
      "status": "RECRUITING",
      "last_update": "2026-06-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06764771",
      "title": "A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03785249",
      "title": "Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04330664",
      "title": "Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)",
      "status": "COMPLETED",
      "last_update": "2025-04-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04793958",
      "title": "Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04975256",
      "title": "Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)",
      "status": "TERMINATED",
      "last_update": "2024-12-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05578092",
      "title": "A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway",
      "status": "TERMINATED",
      "last_update": "2026-02-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05722327",
      "title": "Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06024174",
      "title": "A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06039384",
      "title": "A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation",
      "status": "TERMINATED",
      "last_update": "2026-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07318389",
      "title": "ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AFATINIB": {
    "n": 6,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00801294",
      "title": "A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-12-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01152437",
      "title": "A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2014-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01919879",
      "title": "Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2018-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02450656",
      "title": "Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03785249",
      "title": "Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AFATINIB DIMALEATE": {
    "n": 6,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00801294",
      "title": "A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-12-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01152437",
      "title": "A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2014-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01919879",
      "title": "Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2018-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02450656",
      "title": "Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03785249",
      "title": "Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ALPELISIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01719380",
      "title": "Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02550743",
      "title": "BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study",
      "status": "TERMINATED",
      "last_update": "2021-03-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04753203",
      "title": "Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients",
      "status": "UNKNOWN",
      "last_update": "2023-10-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AMIVANTAMAB": {
    "n": 6,
    "n_observational": 0,
    "n_active": 5,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05379595",
      "title": "A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05845450",
      "title": "Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06662786",
      "title": "A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06750094",
      "title": "A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05395052",
      "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06855849",
      "title": "An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BUPARLISIB": {
    "n": 6,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT01068483",
      "title": "Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients",
      "status": "COMPLETED",
      "last_update": "2020-12-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01304602",
      "title": "A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-01-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01501604",
      "title": "BKM120 in Cancers With PIK3CA Activating Mutations",
      "status": "WITHDRAWN",
      "last_update": "2015-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01571024",
      "title": "BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2017-04-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01576666",
      "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2020-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01591421",
      "title": "P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.",
      "status": "COMPLETED",
      "last_update": "2023-08-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CETUXIMAB": {
    "n": 187,
    "n_observational": 13,
    "n_active": 58,
    "n_withdrawn": 9,
    "trials": [
     {
      "nct": "NCT04687631",
      "title": "Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases",
      "status": "RECRUITING",
      "last_update": "2024-12-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05725200",
      "title": "Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2023-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05797467",
      "title": "Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients",
      "status": "RECRUITING",
      "last_update": "2023-05-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05959356",
      "title": "Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05962502",
      "title": "Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy",
      "status": "RECRUITING",
      "last_update": "2023-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05985954",
      "title": "Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06207656",
      "title": "Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-10-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06226857",
      "title": "Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-01-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06321081",
      "title": "ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06411600",
      "title": "Combination Therapy for BRAF-V600E Metastatic CRCm",
      "status": "RECRUITING",
      "last_update": "2024-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06412198",
      "title": "A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations",
      "status": "RECRUITING",
      "last_update": "2026-06-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06540326",
      "title": "Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab",
      "status": "RECRUITING",
      "last_update": "2025-12-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06586515",
      "title": "MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06720987",
      "title": "A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06764771",
      "title": "A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06835569",
      "title": "A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations",
      "status": "RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06841159",
      "title": "Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1\uff0cChemotherapy and Target Therapy for Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-02-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06856187",
      "title": "Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06917079",
      "title": "BBO-11818 in Adult Subjects With KRAS Mutant Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06922383",
      "title": "A Clinical Study of Arfolitixorin in Patients With mCRC",
      "status": "RECRUITING",
      "last_update": "2026-06-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06978400",
      "title": "A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-05-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07012954",
      "title": "ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC",
      "status": "RECRUITING",
      "last_update": "2025-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07044921",
      "title": "Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.",
      "status": "RECRUITING",
      "last_update": "2025-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07216105",
      "title": "FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07253896",
      "title": "Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab",
      "status": "RECRUITING",
      "last_update": "2025-11-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07411599",
      "title": "Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial (\"Chip-CRC Trial\")",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07474727",
      "title": "A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07549399",
      "title": "SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC",
      "status": "RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07702032",
      "title": "Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07724223",
      "title": "Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC",
      "status": "RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07790510",
      "title": "HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00056030",
      "title": "Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-01-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00063141",
      "title": "Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2010-04-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00077298",
      "title": "Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00079066",
      "title": "Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-08-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00079274",
      "title": "Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer",
      "status": "COMPLETED",
      "last_update": "2026-06-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101348",
      "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer",
      "status": "COMPLETED",
      "last_update": "2014-06-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00125034",
      "title": "Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)",
      "status": "COMPLETED",
      "last_update": "2014-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00182715",
      "title": "Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2013-09-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00227734",
      "title": "Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2012-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00254137",
      "title": "Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.",
      "status": "COMPLETED",
      "last_update": "2010-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00265850",
      "title": "Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-08-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00286130",
      "title": "Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2012-05-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00297128",
      "title": "Preoperative Chemoradiation With Capecitabine and Cetuximab",
      "status": "COMPLETED",
      "last_update": "2011-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00309179",
      "title": "A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00324415",
      "title": "Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00326495",
      "title": "BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00336856",
      "title": "Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy",
      "status": "COMPLETED",
      "last_update": "2016-07-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00353457",
      "title": "Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma",
      "status": "TERMINATED",
      "last_update": "2020-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00362102",
      "title": "A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-11-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00383695",
      "title": "Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2010-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00422773",
      "title": "Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2009-02-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00437268",
      "title": "A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2020-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00438737",
      "title": "Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2011-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00439517",
      "title": "Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.",
      "status": "COMPLETED",
      "last_update": "2014-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00466505",
      "title": "Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2012-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00478634",
      "title": "A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2012-11-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00501410",
      "title": "FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-08-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00522665",
      "title": "Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-05-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00538291",
      "title": "Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment",
      "status": "TERMINATED",
      "last_update": "2014-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00559741",
      "title": "Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2011-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00594984",
      "title": "Phase I/II Combination With Irinotecan- Erbitux",
      "status": "COMPLETED",
      "last_update": "2015-11-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00622674",
      "title": "Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00640081",
      "title": "Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00671372",
      "title": "A Study of Dulanermin Administered in Combination With Camptosar\u00ae/Erbitux\u00ae Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2016-11-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00719199",
      "title": "Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2013-10-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00725400",
      "title": "Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2011-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00766220",
      "title": "Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver",
      "status": "WITHDRAWN",
      "last_update": "2013-01-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00820417",
      "title": "Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib",
      "status": "COMPLETED",
      "last_update": "2009-01-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00845039",
      "title": "A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab",
      "status": "TERMINATED",
      "last_update": "2018-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00925015",
      "title": "Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)",
      "status": "COMPLETED",
      "last_update": "2018-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00954876",
      "title": "Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2022-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00972881",
      "title": "Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-10-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00975897",
      "title": "Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-12-19",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01030042",
      "title": "Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients",
      "status": "COMPLETED",
      "last_update": "2015-07-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01032291",
      "title": "A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2013-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01060423",
      "title": "TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2016-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01086267",
      "title": "Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2016-06-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01161316",
      "title": "Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours",
      "status": "COMPLETED",
      "last_update": "2015-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01166035",
      "title": "Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2010-07-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01212627",
      "title": "Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer",
      "status": "TERMINATED",
      "last_update": "2021-02-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01228734",
      "title": "A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients",
      "status": "COMPLETED",
      "last_update": "2020-01-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01251536",
      "title": "Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-10-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01254617",
      "title": "Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer",
      "status": "COMPLETED",
      "last_update": "2020-03-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01292356",
      "title": "Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response",
      "status": "COMPLETED",
      "last_update": "2017-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01315990",
      "title": "FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema",
      "status": "UNKNOWN",
      "last_update": "2013-12-18",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01322178",
      "title": "Study of Cetuximab in Combination With mFOLFOX-6 (Oxaliplatin, Leucovorin, 5-FU) to Treat Colorectal Liver Metastatic Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2011-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01338558",
      "title": "A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Na\u00efve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab",
      "status": "WITHDRAWN",
      "last_update": "2016-11-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01345526",
      "title": "Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream",
      "status": "COMPLETED",
      "last_update": "2021-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01366118",
      "title": "Study of Therapeutic Targets Tailored Ch and IMRT as Neoadjuvant Treatment in Rectal Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2011-06-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01442649",
      "title": "Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab",
      "status": "COMPLETED",
      "last_update": "2022-01-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01442935",
      "title": "Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases",
      "status": "COMPLETED",
      "last_update": "2021-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01451632",
      "title": "A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2016-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01453257",
      "title": "Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients",
      "status": "COMPLETED",
      "last_update": "2011-10-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01564810",
      "title": "Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2012-10-24",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01609231",
      "title": "A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)",
      "status": "TERMINATED",
      "last_update": "2020-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01637194",
      "title": "Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer",
      "status": "COMPLETED",
      "last_update": "2012-07-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01675999",
      "title": "Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer",
      "status": "UNKNOWN",
      "last_update": "2016-01-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01703910",
      "title": "Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic",
      "status": "COMPLETED",
      "last_update": "2015-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01741038",
      "title": "AlloStim\u00ae In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2020-01-22",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01802645",
      "title": "Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases",
      "status": "UNKNOWN",
      "last_update": "2019-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01832467",
      "title": "Cetuximab Rechallenge Study",
      "status": "COMPLETED",
      "last_update": "2020-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01834014",
      "title": "Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases",
      "status": "COMPLETED",
      "last_update": "2017-08-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01867697",
      "title": "Nordic 8 - A Phase II Trial",
      "status": "COMPLETED",
      "last_update": "2020-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01878422",
      "title": "Sequential Treatment Strategy for Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-01-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01892527",
      "title": "Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects",
      "status": "COMPLETED",
      "last_update": "2022-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01960023",
      "title": "Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2021-10-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02063529",
      "title": "FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2020-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02110082",
      "title": "Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer",
      "status": "COMPLETED",
      "last_update": "2017-04-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02164916",
      "title": "S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2020-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02278133",
      "title": "Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations",
      "status": "COMPLETED",
      "last_update": "2017-10-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02292758",
      "title": "Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2022-01-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02484833",
      "title": "Erbitux MEtastatic Colorectal Cancer Strategy Study",
      "status": "COMPLETED",
      "last_update": "2020-03-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02508077",
      "title": "FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2018-08-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02563002",
      "title": "Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)",
      "status": "COMPLETED",
      "last_update": "2024-10-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02630420",
      "title": "Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2017-10-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02675946",
      "title": "CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)",
      "status": "UNKNOWN",
      "last_update": "2022-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02717923",
      "title": "A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2017-10-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02826837",
      "title": "LEAC-102 for Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2021-10-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02953782",
      "title": "Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-03-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978313",
      "title": "Cetuximab Monotherapy Maintenance Treatment in mCRC",
      "status": "UNKNOWN",
      "last_update": "2016-11-30",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03135652",
      "title": "Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation",
      "status": "WITHDRAWN",
      "last_update": "2024-01-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03164655",
      "title": "Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network",
      "status": "COMPLETED",
      "last_update": "2024-10-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03169777",
      "title": "QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC",
      "status": "WITHDRAWN",
      "last_update": "2025-02-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03186326",
      "title": "Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2025-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03251612",
      "title": "Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03391934",
      "title": "Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux\u00ae (Merck) in Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-04-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03524820",
      "title": "Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2022-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03567629",
      "title": "Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693807",
      "title": "A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma",
      "status": "COMPLETED",
      "last_update": "2026-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03803553",
      "title": "Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03944252",
      "title": "Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)",
      "status": "UNKNOWN",
      "last_update": "2019-07-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04117945",
      "title": "Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04160416",
      "title": "mXELOXIRI Combined With Molecular Targeted Drug in mCRC",
      "status": "UNKNOWN",
      "last_update": "2019-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04224415",
      "title": "Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC",
      "status": "COMPLETED",
      "last_update": "2023-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04466254",
      "title": "Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2021-08-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04509635",
      "title": "Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis",
      "status": "UNKNOWN",
      "last_update": "2020-08-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04513951",
      "title": "AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2025-01-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04616196",
      "title": "Study of NKTR 255 in Combination With Cetuximab in Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04668976",
      "title": "A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-12-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04670679",
      "title": "A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04745130",
      "title": "Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)",
      "status": "UNKNOWN",
      "last_update": "2023-02-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04776655",
      "title": "Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04833036",
      "title": "c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI",
      "status": "UNKNOWN",
      "last_update": "2021-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04835142",
      "title": "Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC",
      "status": "COMPLETED",
      "last_update": "2026-05-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04853043",
      "title": "Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2025-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05004350",
      "title": "A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.",
      "status": "COMPLETED",
      "last_update": "2026-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05039177",
      "title": "A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-03-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05074966",
      "title": "The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts",
      "status": "UNKNOWN",
      "last_update": "2021-10-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05143099",
      "title": "Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC",
      "status": "UNKNOWN",
      "last_update": "2023-03-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05160896",
      "title": "SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05194995",
      "title": "JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05217069",
      "title": "FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC",
      "status": "COMPLETED",
      "last_update": "2025-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05239741",
      "title": "Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05278351",
      "title": "Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC",
      "status": "UNKNOWN",
      "last_update": "2023-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05308446",
      "title": "Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05409417",
      "title": "Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status",
      "status": "UNKNOWN",
      "last_update": "2022-06-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05497336",
      "title": "A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2026-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05510895",
      "title": "Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-10-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05540951",
      "title": "VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2022-09-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05674526",
      "title": "A Phase 1b Study of WU-NK-101 in Combination With Cetuximab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-04-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05694936",
      "title": "Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05710406",
      "title": "Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05720559",
      "title": "Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection",
      "status": "UNKNOWN",
      "last_update": "2023-02-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05743036",
      "title": "ZN-c3 in Adult Participants With Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2025-08-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05797883",
      "title": "FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu \u00ae) in the Treatment of Unresectable or Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05873972",
      "title": "Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient",
      "status": "UNKNOWN",
      "last_update": "2023-05-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06011772",
      "title": "EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06035133",
      "title": "Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-09-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06231017",
      "title": "Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06358430",
      "title": "Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06575127",
      "title": "Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study",
      "status": "UNKNOWN",
      "last_update": "2024-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06578559",
      "title": "Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06908031",
      "title": "SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06959589",
      "title": "The Efficacy and Safety of IBI351, Cetuximab \u03b2 Combined With FOLFIRI as First-line /IBI351, Cetuximab \u03b2 as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07070713",
      "title": "Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07079462",
      "title": "Comparing 18F-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07094893",
      "title": "Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07178717",
      "title": "A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07209384",
      "title": "Clinical Efficacy of Transarterial Chemoembolization in Elderly Patients With Advanced Unresectable Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-10-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07446270",
      "title": "Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07503639",
      "title": "Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07509398",
      "title": "FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-03",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07515963",
      "title": "FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07551778",
      "title": "Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07683403",
      "title": "Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07691489",
      "title": "A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CONTUSUGENE LADENOVEC": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02842125",
      "title": "Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer",
      "status": "TERMINATED",
      "last_update": "2020-06-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "COPANLISIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03711058",
      "title": "Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-09-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DABRAFENIB": {
    "n": 11,
    "n_observational": 0,
    "n_active": 7,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06978400",
      "title": "A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-05-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07440290",
      "title": "DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07506109",
      "title": "A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01750918",
      "title": "BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)",
      "status": "COMPLETED",
      "last_update": "2021-10-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03668431",
      "title": "Dabrafenib + Trametinib + PDR001 In Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2022-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04294160",
      "title": "A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2025-12-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04439292",
      "title": "Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05963087",
      "title": "Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-07-27",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06967155",
      "title": "A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07714447",
      "title": "Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DACOMITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02039336",
      "title": "Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC",
      "status": "COMPLETED",
      "last_update": "2025-07-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DEPATUXIZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02365662",
      "title": "A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor",
      "status": "TERMINATED",
      "last_update": "2018-03-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DEPATUXIZUMAB MAFODOTIN": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02365662",
      "title": "A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor",
      "status": "TERMINATED",
      "last_update": "2018-03-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DISITAMAB VEDOTIN": {
    "n": 5,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05333809",
      "title": "Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2022-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05493683",
      "title": "Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2022-10-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05578287",
      "title": "RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05661357",
      "title": "Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression",
      "status": "UNKNOWN",
      "last_update": "2024-04-17",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07509424",
      "title": "Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DS-7423": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01364844",
      "title": "Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors",
      "status": "COMPLETED",
      "last_update": "2014-02-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ENCORAFENIB": {
    "n": 34,
    "n_observational": 2,
    "n_active": 20,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05443087",
      "title": "TARGETed Therapy Drug MONITOring in DIGestive Oncology",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05639413",
      "title": "A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-12-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05706779",
      "title": "Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer",
      "status": "RECRUITING",
      "last_update": "2025-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05725200",
      "title": "Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2023-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05985954",
      "title": "Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06102902",
      "title": "Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06207656",
      "title": "Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-10-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06411600",
      "title": "Combination Therapy for BRAF-V600E Metastatic CRCm",
      "status": "RECRUITING",
      "last_update": "2024-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06640166",
      "title": "Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.",
      "status": "RECRUITING",
      "last_update": "2025-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07789210",
      "title": "A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01436656",
      "title": "A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-10-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01719380",
      "title": "Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02278133",
      "title": "Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations",
      "status": "COMPLETED",
      "last_update": "2017-10-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02675946",
      "title": "CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)",
      "status": "UNKNOWN",
      "last_update": "2022-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02857270",
      "title": "A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2022-11-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02928224",
      "title": "Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-12-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693170",
      "title": "Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03803553",
      "title": "Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04017650",
      "title": "Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04044430",
      "title": "Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2023-01-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04607421",
      "title": "A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04800822",
      "title": "PF-07284892 in Participants With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05004350",
      "title": "A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.",
      "status": "COMPLETED",
      "last_update": "2026-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05039177",
      "title": "A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-03-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05217446",
      "title": "A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05308446",
      "title": "Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05510895",
      "title": "Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-10-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05576896",
      "title": "Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory",
      "status": "TERMINATED",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05710406",
      "title": "Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05743036",
      "title": "ZN-c3 in Adult Participants With Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2025-08-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06578559",
      "title": "Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07178717",
      "title": "A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07318389",
      "title": "ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07714447",
      "title": "Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ENTRECTINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02568267",
      "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644315",
      "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ERLOTINIB": {
    "n": 33,
    "n_observational": 2,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00030498",
      "title": "Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction",
      "status": "COMPLETED",
      "last_update": "2013-01-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00032110",
      "title": "Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00047762",
      "title": "Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2005-06-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00049101",
      "title": "Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00060411",
      "title": "A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101348",
      "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer",
      "status": "COMPLETED",
      "last_update": "2014-06-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00116506",
      "title": "Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2007-12-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00118261",
      "title": "Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2012-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00123851",
      "title": "Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2009-04-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00265824",
      "title": "Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)",
      "status": "COMPLETED",
      "last_update": "2015-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00307736",
      "title": "Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-05-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00397384",
      "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00459901",
      "title": "Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2015-04-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00543842",
      "title": "Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-02-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00598156",
      "title": "Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva",
      "status": "COMPLETED",
      "last_update": "2013-04-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00600496",
      "title": "A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)",
      "status": "COMPLETED",
      "last_update": "2026-05-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00603356",
      "title": "Phase I Study of OSI-930 and Erlotinib in Cancer Tumors",
      "status": "COMPLETED",
      "last_update": "2011-09-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00642746",
      "title": "Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)",
      "status": "TERMINATED",
      "last_update": "2014-09-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00739453",
      "title": "A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva\u00ae)",
      "status": "COMPLETED",
      "last_update": "2024-11-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00754494",
      "title": "Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma",
      "status": "COMPLETED",
      "last_update": "2015-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00784667",
      "title": "Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib",
      "status": "UNKNOWN",
      "last_update": "2010-11-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00910676",
      "title": "Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors",
      "status": "COMPLETED",
      "last_update": "2012-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00940316",
      "title": "Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01135498",
      "title": "A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.",
      "status": "COMPLETED",
      "last_update": "2015-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01187901",
      "title": "A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients",
      "status": "COMPLETED",
      "last_update": "2016-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01229813",
      "title": "Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.",
      "status": "COMPLETED",
      "last_update": "2015-04-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01243047",
      "title": "Intermittent Versus Continuous Tarceva Study",
      "status": "COMPLETED",
      "last_update": "2012-11-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01703910",
      "title": "Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic",
      "status": "COMPLETED",
      "last_update": "2015-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02723578",
      "title": "Pemetrexed and Erlotinib for Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2020-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02961374",
      "title": "Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer",
      "status": "COMPLETED",
      "last_update": "2022-07-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03086538",
      "title": "Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2022-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04165031",
      "title": "A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation",
      "status": "TERMINATED",
      "last_update": "2021-11-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04449874",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FUTUXIMAB": {
    "n": 8,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT01117428",
      "title": "Sym004 in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2018-10-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02083653",
      "title": "Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02568046",
      "title": "Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients",
      "status": "TERMINATED",
      "last_update": "2019-03-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02965417",
      "title": "Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients",
      "status": "WITHDRAWN",
      "last_update": "2017-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03549338",
      "title": "Sym004 Versus Futuximab or Modotuximab in Patients With mCRC",
      "status": "TERMINATED",
      "last_update": "2020-09-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03717038",
      "title": "Sym004 Versus TAS-102 in Patients With mCRC",
      "status": "WITHDRAWN",
      "last_update": "2019-02-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05162755",
      "title": "S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers",
      "status": "COMPLETED",
      "last_update": "2026-05-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05223673",
      "title": "Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2024-08-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "GC1118": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02352571",
      "title": "Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer",
      "status": "UNKNOWN",
      "last_update": "2016-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03454620",
      "title": "A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2022-03-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "GEDATOLISIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01925274",
      "title": "A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2019-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01937715",
      "title": "A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2016-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "GEFITINIB": {
    "n": 11,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT00025142",
      "title": "Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00025350",
      "title": "Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00026299",
      "title": "Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-09-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00026364",
      "title": "ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-03-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00030524",
      "title": "ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2012-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00052585",
      "title": "Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2013-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00087334",
      "title": "Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2013-02-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00233623",
      "title": "Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2011-01-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00234429",
      "title": "A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma",
      "status": "COMPLETED",
      "last_update": "2007-12-18",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00242788",
      "title": "IRESSA\u2122 In Combo With Xeloda\u2122 in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure",
      "status": "COMPLETED",
      "last_update": "2009-04-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00820417",
      "title": "Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib",
      "status": "COMPLETED",
      "last_update": "2009-01-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IDASANUTLIN": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03555149",
      "title": "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)",
      "status": "TERMINATED",
      "last_update": "2023-11-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IMGATUZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01326000",
      "title": "A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2022-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "INAVOLISIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04929223",
      "title": "A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04449874",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07323576",
      "title": "A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2026-02-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "KBP5209": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02442414",
      "title": "A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "KN-026": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05985707",
      "title": "KN026 Plus Chemotherapy \u00b1 KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LABETUZUMAB": {
    "n": 7,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT00040599",
      "title": "Safety Study of 90Y-hMN14 to Treat Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00041652",
      "title": "Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer",
      "status": "COMPLETED",
      "last_update": "2021-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00041691",
      "title": "Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery",
      "status": "TERMINATED",
      "last_update": "2021-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01270698",
      "title": "Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01605318",
      "title": "Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2024-01-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01915472",
      "title": "A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2021-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03699332",
      "title": "Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin",
      "status": "UNKNOWN",
      "last_update": "2019-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LABETUZUMAB GOVITECAN": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01270698",
      "title": "Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01605318",
      "title": "Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2024-01-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LAPATINIB": {
    "n": 8,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00044343",
      "title": "GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin",
      "status": "COMPLETED",
      "last_update": "2014-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00536809",
      "title": "Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00574171",
      "title": "Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma",
      "status": "COMPLETED",
      "last_update": "2019-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01184482",
      "title": "Lapatinib and Cetuximab in Patients With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2013-10-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01847599",
      "title": "Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib",
      "status": "TERMINATED",
      "last_update": "2017-07-21",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02230553",
      "title": "Lapatinib Plus Trametinib in KRAS Mutant NSCLC",
      "status": "COMPLETED",
      "last_update": "2025-07-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03225937",
      "title": "Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03418558",
      "title": "Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.",
      "status": "UNKNOWN",
      "last_update": "2018-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LAPATINIB DITOSYLATE": {
    "n": 8,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00044343",
      "title": "GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin",
      "status": "COMPLETED",
      "last_update": "2014-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00536809",
      "title": "Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00574171",
      "title": "Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma",
      "status": "COMPLETED",
      "last_update": "2019-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01184482",
      "title": "Lapatinib and Cetuximab in Patients With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2013-10-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01847599",
      "title": "Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib",
      "status": "TERMINATED",
      "last_update": "2017-07-21",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02230553",
      "title": "Lapatinib Plus Trametinib in KRAS Mutant NSCLC",
      "status": "COMPLETED",
      "last_update": "2025-07-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03225937",
      "title": "Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03418558",
      "title": "Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.",
      "status": "UNKNOWN",
      "last_update": "2018-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LAROTRECTINIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05725200",
      "title": "Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2023-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02576431",
      "title": "A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LY-3009120": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02014116",
      "title": "A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body",
      "status": "TERMINATED",
      "last_update": "2019-12-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MATUZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05239650",
      "title": "Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2022-05-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MODOTUXIMAB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT02083653",
      "title": "Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03549338",
      "title": "Sym004 Versus Futuximab or Modotuximab in Patients With mCRC",
      "status": "TERMINATED",
      "last_update": "2020-09-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03717038",
      "title": "Sym004 Versus TAS-102 in Patients With mCRC",
      "status": "WITHDRAWN",
      "last_update": "2019-02-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05162755",
      "title": "S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers",
      "status": "COMPLETED",
      "last_update": "2026-05-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05223673",
      "title": "Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2024-08-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MUBRITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00034281",
      "title": "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2",
      "status": "COMPLETED",
      "last_update": "2012-02-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NAPORAFENIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04294160",
      "title": "A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2025-12-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05907304",
      "title": "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NAZARTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02900664",
      "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris\u00ae (Canakinumab) or Mekinist\u00ae (Trametinib)",
      "status": "COMPLETED",
      "last_update": "2022-03-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NECITUMUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00835185",
      "title": "Study of IMC-11F8 in Participants With Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2016-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NERATINIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT01960023",
      "title": "Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2021-10-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03457896",
      "title": "Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status",
      "status": "UNKNOWN",
      "last_update": "2022-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03919292",
      "title": "Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca",
      "status": "SUSPENDED",
      "last_update": "2026-06-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NIMOTUZUMAB": {
    "n": 7,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04235114",
      "title": "Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)",
      "status": "RECRUITING",
      "last_update": "2024-01-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00493857",
      "title": "Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2008-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00972465",
      "title": "Study of Nimotuzumab to Treat Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2009-09-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05278728",
      "title": "Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-02-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06022276",
      "title": "Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-09-01",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06343116",
      "title": "Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-04-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07446270",
      "title": "Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OMIPALISIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OSIMERTINIB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03989115",
      "title": "Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC",
      "status": "COMPLETED",
      "last_update": "2023-06-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04868877",
      "title": "Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05647122",
      "title": "First in Human Study of AZD9592 in Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05954871",
      "title": "Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PANITUMUMAB": {
    "n": 163,
    "n_observational": 19,
    "n_active": 36,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT02885753",
      "title": "Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver",
      "status": "RECRUITING",
      "last_update": "2025-07-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05007132",
      "title": "Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05786924",
      "title": "Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05845450",
      "title": "Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05863195",
      "title": "Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06226857",
      "title": "Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-01-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06245356",
      "title": "Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-12-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06252649",
      "title": "Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-na\u00efve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06490536",
      "title": "The Sagittarius Trial",
      "status": "RECRUITING",
      "last_update": "2025-08-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06509126",
      "title": "Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-07-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06714357",
      "title": "ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06728072",
      "title": "Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06820463",
      "title": "A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06922383",
      "title": "A Clinical Study of Arfolitixorin in Patients With mCRC",
      "status": "RECRUITING",
      "last_update": "2026-06-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06978400",
      "title": "A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-05-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06983743",
      "title": "A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07094113",
      "title": "AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07094204",
      "title": "A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07201519",
      "title": "Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy",
      "status": "RECRUITING",
      "last_update": "2026-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07543744",
      "title": "A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix\u00ae in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07659795",
      "title": "A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004879",
      "title": "Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer",
      "status": "COMPLETED",
      "last_update": "2013-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00039273",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00083616",
      "title": "Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2014-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00089635",
      "title": "Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2022-11-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101894",
      "title": "Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2012-09-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00111761",
      "title": "Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-12-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00111774",
      "title": "Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma",
      "status": "COMPLETED",
      "last_update": "2013-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00113763",
      "title": "Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2022-11-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00113776",
      "title": "Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2011-01-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00115765",
      "title": "PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study",
      "status": "COMPLETED",
      "last_update": "2018-10-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00327119",
      "title": "Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2009-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00332163",
      "title": "Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy",
      "status": "COMPLETED",
      "last_update": "2016-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00339183",
      "title": "Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone",
      "status": "COMPLETED",
      "last_update": "2022-09-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00346099",
      "title": "Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum",
      "status": "WITHDRAWN",
      "last_update": "2008-01-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00364013",
      "title": "PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy",
      "status": "COMPLETED",
      "last_update": "2022-11-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00389870",
      "title": "Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil",
      "status": "COMPLETED",
      "last_update": "2022-06-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00411450",
      "title": "Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment",
      "status": "COMPLETED",
      "last_update": "2016-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00418938",
      "title": "SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial",
      "status": "COMPLETED",
      "last_update": "2018-10-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00425204",
      "title": "Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment",
      "status": "COMPLETED",
      "last_update": "2008-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00475293",
      "title": "Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC",
      "status": "COMPLETED",
      "last_update": "2013-09-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00508404",
      "title": "Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00563316",
      "title": "Effect of Panitumumab on the Pharmacokinetics of Irinotecan",
      "status": "COMPLETED",
      "last_update": "2016-04-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00630786",
      "title": "Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study",
      "status": "COMPLETED",
      "last_update": "2014-02-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00647530",
      "title": "Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery",
      "status": "UNKNOWN",
      "last_update": "2019-05-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00655499",
      "title": "Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00788957",
      "title": "Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)",
      "status": "COMPLETED",
      "last_update": "2024-08-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00792363",
      "title": "Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations",
      "status": "COMPLETED",
      "last_update": "2012-06-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00814619",
      "title": "Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer",
      "status": "COMPLETED",
      "last_update": "2014-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00819780",
      "title": "PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors",
      "status": "COMPLETED",
      "last_update": "2022-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00842257",
      "title": "Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-05-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00853931",
      "title": "Biomarker - Panitumumab Response With KRAS Wild Type MCC",
      "status": "COMPLETED",
      "last_update": "2015-12-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00867334",
      "title": "New Individualized Therapy Trial for Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2020-06-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00879385",
      "title": "KRAS Wild-type Metastatic Colorectal Cancer Trial",
      "status": "COMPLETED",
      "last_update": "2014-10-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00885885",
      "title": "Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases",
      "status": "COMPLETED",
      "last_update": "2017-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00891930",
      "title": "Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab",
      "status": "COMPLETED",
      "last_update": "2024-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00940316",
      "title": "Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00950820",
      "title": "Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2013-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00958386",
      "title": "Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)",
      "status": "COMPLETED",
      "last_update": "2015-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00967655",
      "title": "Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2014-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00973193",
      "title": "Preoperative Panitumumab and Radiotherapy in Rectal Cancer",
      "status": "TERMINATED",
      "last_update": "2016-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01001377",
      "title": "ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2022-09-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01057017",
      "title": "First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras",
      "status": "TERMINATED",
      "last_update": "2020-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01108107",
      "title": "Neoadjuvant Treatment of Colon Cancer",
      "status": "COMPLETED",
      "last_update": "2015-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01110785",
      "title": "Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2013-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01126112",
      "title": "Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01139138",
      "title": "Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-11-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01144195",
      "title": "A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed \u2265 6 Months After the Last Dose of the First Line Chemotherapy",
      "status": "UNKNOWN",
      "last_update": "2010-11-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01215539",
      "title": "Study of Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2015-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01226719",
      "title": "FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only",
      "status": "COMPLETED",
      "last_update": "2015-05-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01257360",
      "title": "Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)",
      "status": "UNKNOWN",
      "last_update": "2016-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01260415",
      "title": "A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases",
      "status": "COMPLETED",
      "last_update": "2019-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01285778",
      "title": "Vectibix for the Treatment of Anal Cancer",
      "status": "COMPLETED",
      "last_update": "2018-05-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01288339",
      "title": "Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2018-05-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01312857",
      "title": "Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01328171",
      "title": "FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)",
      "status": "COMPLETED",
      "last_update": "2023-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01358812",
      "title": "FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-03-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01384994",
      "title": "Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients",
      "status": "UNKNOWN",
      "last_update": "2012-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01412957",
      "title": "Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-03-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01418742",
      "title": "SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment",
      "status": "TERMINATED",
      "last_update": "2014-07-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01443377",
      "title": "Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01504477",
      "title": "Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2020-03-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01508000",
      "title": "Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases",
      "status": "TERMINATED",
      "last_update": "2016-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01591421",
      "title": "P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.",
      "status": "COMPLETED",
      "last_update": "2023-08-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01668498",
      "title": "Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2016-04-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01704703",
      "title": "Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques",
      "status": "COMPLETED",
      "last_update": "2017-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01750918",
      "title": "BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)",
      "status": "COMPLETED",
      "last_update": "2021-10-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01776307",
      "title": "A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-11-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01791309",
      "title": "Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2016-01-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01801904",
      "title": "A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01814501",
      "title": "Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab",
      "status": "COMPLETED",
      "last_update": "2025-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01895257",
      "title": "Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2017-07-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01910610",
      "title": "Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-03-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01927341",
      "title": "Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors",
      "status": "COMPLETED",
      "last_update": "2021-02-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01991873",
      "title": "Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02008383",
      "title": "Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-02-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02015923",
      "title": "Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases",
      "status": "TERMINATED",
      "last_update": "2021-03-16",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02162563",
      "title": "Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases",
      "status": "COMPLETED",
      "last_update": "2025-02-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02199223",
      "title": "Regorafenib + Panitumumab for Colorectal Cancers",
      "status": "TERMINATED",
      "last_update": "2016-09-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02205398",
      "title": "Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy",
      "status": "TERMINATED",
      "last_update": "2019-01-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02301962",
      "title": "Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2019-12-16",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02337946",
      "title": "Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-na\u00efve Unresectable Advanced Recurrent Colorectal Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02394795",
      "title": "Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC",
      "status": "COMPLETED",
      "last_update": "2023-11-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02399943",
      "title": "A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2022-05-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02448810",
      "title": "Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2021-05-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02476045",
      "title": "Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)",
      "status": "UNKNOWN",
      "last_update": "2016-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02508077",
      "title": "FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2018-08-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02613221",
      "title": "A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-07-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02904031",
      "title": "Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients",
      "status": "UNKNOWN",
      "last_update": "2020-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02934529",
      "title": "Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab",
      "status": "COMPLETED",
      "last_update": "2025-04-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02980510",
      "title": "Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03000374",
      "title": "Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery",
      "status": "COMPLETED",
      "last_update": "2022-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03069950",
      "title": "Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver",
      "status": "WITHDRAWN",
      "last_update": "2019-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03087071",
      "title": "Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03142516",
      "title": "FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status",
      "status": "COMPLETED",
      "last_update": "2021-06-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03164655",
      "title": "Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network",
      "status": "COMPLETED",
      "last_update": "2024-10-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03167268",
      "title": "Panitumumab Skin Toxicity Prevention Trial",
      "status": "UNKNOWN",
      "last_update": "2021-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03186326",
      "title": "Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2025-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03227926",
      "title": "Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance",
      "status": "COMPLETED",
      "last_update": "2022-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03231722",
      "title": "First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS",
      "status": "COMPLETED",
      "last_update": "2023-01-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03251612",
      "title": "Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03263429",
      "title": "Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-08-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03300609",
      "title": "5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab",
      "status": "TERMINATED",
      "last_update": "2020-06-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03311750",
      "title": "Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2021-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03366155",
      "title": "Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver",
      "status": "COMPLETED",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03428958",
      "title": "A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment",
      "status": "COMPLETED",
      "last_update": "2025-04-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03442569",
      "title": "PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC",
      "status": "COMPLETED",
      "last_update": "2025-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03584711",
      "title": "FOLFOX + Panitumumab According to a \"Stop and go\" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation",
      "status": "COMPLETED",
      "last_update": "2025-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03635021",
      "title": "Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693807",
      "title": "A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma",
      "status": "COMPLETED",
      "last_update": "2026-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03751176",
      "title": "Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal",
      "status": "UNKNOWN",
      "last_update": "2021-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03764137",
      "title": "Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2025-01-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03803436",
      "title": "Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation",
      "status": "UNKNOWN",
      "last_update": "2023-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03940131",
      "title": "Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR",
      "status": "UNKNOWN",
      "last_update": "2022-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03983993",
      "title": "Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03992456",
      "title": "Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04034173",
      "title": "Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation",
      "status": "TERMINATED",
      "last_update": "2026-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04117945",
      "title": "Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04169347",
      "title": "FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04276090",
      "title": "Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma",
      "status": "TERMINATED",
      "last_update": "2023-07-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04342676",
      "title": "Lymph Node Ratio and Kras Mutation in R Colon Cancer",
      "status": "COMPLETED",
      "last_update": "2020-04-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04425239",
      "title": "Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2022-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04515394",
      "title": "Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)",
      "status": "TERMINATED",
      "last_update": "2022-12-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04587128",
      "title": "Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04668976",
      "title": "A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-12-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04735900",
      "title": "lead-in FOLICOLOR Trial: Following Therapy Response Through Liquid Biopsy in Metastatic Colorectal Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2021-02-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04787341",
      "title": "PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence",
      "status": "COMPLETED",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05084859",
      "title": "A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-08-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05121038",
      "title": "CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05198934",
      "title": "Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation",
      "status": "COMPLETED",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05468892",
      "title": "Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial",
      "status": "COMPLETED",
      "last_update": "2024-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05576896",
      "title": "Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory",
      "status": "TERMINATED",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05694936",
      "title": "Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05862051",
      "title": "RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06011772",
      "title": "EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06194877",
      "title": "A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers",
      "status": "TERMINATED",
      "last_update": "2025-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06268015",
      "title": "Botensilimab and Balstilimab Optimization in Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06332079",
      "title": "Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients",
      "status": "TERMINATED",
      "last_update": "2026-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06575127",
      "title": "Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study",
      "status": "UNKNOWN",
      "last_update": "2024-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06967155",
      "title": "A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07124884",
      "title": "5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07318389",
      "title": "ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07509398",
      "title": "FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-03",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PELITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00072748",
      "title": "Study Evaluating EKB-569 in Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2009-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PERTUZUMAB": {
    "n": 12,
    "n_observational": 1,
    "n_active": 6,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05786716",
      "title": "DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations",
      "status": "RECRUITING",
      "last_update": "2025-12-02",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06490536",
      "title": "The Sagittarius Trial",
      "status": "RECRUITING",
      "last_update": "2025-08-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07108127",
      "title": "Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00551421",
      "title": "Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-03-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01376505",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-09-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02291289",
      "title": "A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)",
      "status": "COMPLETED",
      "last_update": "2024-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03225937",
      "title": "Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03323424",
      "title": "Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers",
      "status": "WITHDRAWN",
      "last_update": "2020-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03365882",
      "title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2026-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03803553",
      "title": "Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06136897",
      "title": "Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "POZIOTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04172597",
      "title": "A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2024-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PYROTINIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03843749",
      "title": "Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.",
      "status": "UNKNOWN",
      "last_update": "2019-02-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04227041",
      "title": "A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2020-01-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04380012",
      "title": "A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2021-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05350917",
      "title": "Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy",
      "status": "UNKNOWN",
      "last_update": "2022-05-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "REGORAFENIB": {
    "n": 146,
    "n_observational": 25,
    "n_active": 42,
    "n_withdrawn": 8,
    "trials": [
     {
      "nct": "NCT04701476",
      "title": "TATE and Pembrolizumab (MK3475) in mCRC and NSCLC",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05057052",
      "title": "Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis",
      "status": "RECRUITING",
      "last_update": "2025-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05443087",
      "title": "TARGETed Therapy Drug MONITOring in DIGestive Oncology",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05462613",
      "title": "Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-12-20",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05794971",
      "title": "Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases",
      "status": "RECRUITING",
      "last_update": "2023-05-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05963490",
      "title": "Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05985109",
      "title": "KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2023-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06425133",
      "title": "Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers",
      "status": "RECRUITING",
      "last_update": "2024-12-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06456515",
      "title": "Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC",
      "status": "RECRUITING",
      "last_update": "2025-02-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06558773",
      "title": "GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.",
      "status": "RECRUITING",
      "last_update": "2026-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06829355",
      "title": "\"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer\"",
      "status": "RECRUITING",
      "last_update": "2025-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06887218",
      "title": "5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06911684",
      "title": "Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.",
      "status": "RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06930118",
      "title": "The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.",
      "status": "RECRUITING",
      "last_update": "2025-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06949982",
      "title": "Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes",
      "status": "RECRUITING",
      "last_update": "2025-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06992648",
      "title": "Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-05-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07003022",
      "title": "Phase \u2161 Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC",
      "status": "RECRUITING",
      "last_update": "2025-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07071961",
      "title": "Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07213570",
      "title": "STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07343791",
      "title": "Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.",
      "status": "RECRUITING",
      "last_update": "2026-01-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07722494",
      "title": "IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00934882",
      "title": "Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI",
      "status": "COMPLETED",
      "last_update": "2014-06-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01103323",
      "title": "Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy",
      "status": "COMPLETED",
      "last_update": "2015-06-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01189903",
      "title": "Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2014-01-28",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01289821",
      "title": "First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib",
      "status": "COMPLETED",
      "last_update": "2017-03-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01298570",
      "title": "Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01584830",
      "title": "Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy",
      "status": "COMPLETED",
      "last_update": "2016-02-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01786538",
      "title": "Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines",
      "status": "WITHDRAWN",
      "last_update": "2013-03-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01853319",
      "title": "Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy",
      "status": "COMPLETED",
      "last_update": "2019-04-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01875380",
      "title": "Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01896856",
      "title": "Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2020-10-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01929616",
      "title": "Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)",
      "status": "COMPLETED",
      "last_update": "2019-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01939223",
      "title": "Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy",
      "status": "TERMINATED",
      "last_update": "2017-10-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01949194",
      "title": "Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers",
      "status": "UNKNOWN",
      "last_update": "2018-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01996969",
      "title": "Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-02-22",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02096354",
      "title": "A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-10-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02116894",
      "title": "Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-03-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02119676",
      "title": "Study of Ruxolitinib in Colorectal Cancer Patients",
      "status": "TERMINATED",
      "last_update": "2018-02-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02175095",
      "title": "[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib",
      "status": "COMPLETED",
      "last_update": "2024-10-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02175654",
      "title": "Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab",
      "status": "TERMINATED",
      "last_update": "2017-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02195011",
      "title": "Safety Study of Regorafenib and SIR-Spheres\u00ae Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases",
      "status": "COMPLETED",
      "last_update": "2023-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02199223",
      "title": "Regorafenib + Panitumumab for Colorectal Cancers",
      "status": "TERMINATED",
      "last_update": "2016-09-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02287025",
      "title": "A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?",
      "status": "TERMINATED",
      "last_update": "2017-10-19",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02287727",
      "title": "Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment",
      "status": "WITHDRAWN",
      "last_update": "2016-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02288078",
      "title": "Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)",
      "status": "UNKNOWN",
      "last_update": "2014-11-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02316340",
      "title": "Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02368886",
      "title": "Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02402036",
      "title": "A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2019-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02425683",
      "title": "Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX",
      "status": "TERMINATED",
      "last_update": "2020-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465502",
      "title": "Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2018-11-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02466009",
      "title": "Regorafenib in Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02581059",
      "title": "Efficacy of Ginseng for Patients on Regorafenib",
      "status": "TERMINATED",
      "last_update": "2024-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02619435",
      "title": "Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02651415",
      "title": "Phase II Study of Perindopril and Regorafenib in mCRC",
      "status": "COMPLETED",
      "last_update": "2019-09-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02664077",
      "title": "A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer",
      "status": "TERMINATED",
      "last_update": "2022-04-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02699073",
      "title": "Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib",
      "status": "COMPLETED",
      "last_update": "2019-02-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02788279",
      "title": "A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)",
      "status": "COMPLETED",
      "last_update": "2019-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02800330",
      "title": "The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib",
      "status": "COMPLETED",
      "last_update": "2018-08-02",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02835924",
      "title": "Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC",
      "status": "COMPLETED",
      "last_update": "2020-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02910843",
      "title": "Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer",
      "status": "TERMINATED",
      "last_update": "2023-01-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02934529",
      "title": "Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab",
      "status": "COMPLETED",
      "last_update": "2025-04-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02955940",
      "title": "An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03081494",
      "title": "Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2020-12-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03099486",
      "title": "Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC",
      "status": "TERMINATED",
      "last_update": "2022-02-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03215264",
      "title": "To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-11-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03251378",
      "title": "A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers",
      "status": "COMPLETED",
      "last_update": "2024-09-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03251612",
      "title": "Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03305913",
      "title": "Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy",
      "status": "COMPLETED",
      "last_update": "2021-03-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03377361",
      "title": "An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread",
      "status": "COMPLETED",
      "last_update": "2025-12-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03475953",
      "title": "A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-03-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03555149",
      "title": "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)",
      "status": "TERMINATED",
      "last_update": "2023-11-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03563157",
      "title": "QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine",
      "status": "TERMINATED",
      "last_update": "2024-12-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03564938",
      "title": "Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).",
      "status": "COMPLETED",
      "last_update": "2024-12-03",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03657641",
      "title": "Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03698253",
      "title": "Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI",
      "status": "COMPLETED",
      "last_update": "2018-10-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03712943",
      "title": "Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-02-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03828799",
      "title": "Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-02-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03829462",
      "title": "Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03844620",
      "title": "Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03880877",
      "title": "Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2019-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03890731",
      "title": "A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed",
      "status": "COMPLETED",
      "last_update": "2024-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03898102",
      "title": "Zinc Supplement in Regorafenib Treated mCRC Patient",
      "status": "COMPLETED",
      "last_update": "2019-04-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03946917",
      "title": "JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2020-05-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03992456",
      "title": "Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04008511",
      "title": "Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2019-07-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04030260",
      "title": "Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-03-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04110093",
      "title": "Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2020-12-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04117945",
      "title": "Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04126733",
      "title": "Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)",
      "status": "COMPLETED",
      "last_update": "2023-07-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04362839",
      "title": "Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-01-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04446091",
      "title": "A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)",
      "status": "UNKNOWN",
      "last_update": "2020-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04450836",
      "title": "Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2025-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04503694",
      "title": "Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04534218",
      "title": "Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-12-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04660812",
      "title": "An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.",
      "status": "COMPLETED",
      "last_update": "2025-10-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04745130",
      "title": "Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)",
      "status": "UNKNOWN",
      "last_update": "2023-02-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04775862",
      "title": "A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.",
      "status": "UNKNOWN",
      "last_update": "2021-03-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04776148",
      "title": "Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)",
      "status": "COMPLETED",
      "last_update": "2026-02-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04787341",
      "title": "PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence",
      "status": "COMPLETED",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04819516",
      "title": "Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2021-03-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04874207",
      "title": "Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib",
      "status": "COMPLETED",
      "last_update": "2025-08-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05064059",
      "title": "A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)",
      "status": "COMPLETED",
      "last_update": "2026-05-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05130021",
      "title": "A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2021-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05198934",
      "title": "Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation",
      "status": "COMPLETED",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05278351",
      "title": "Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC",
      "status": "UNKNOWN",
      "last_update": "2023-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05289726",
      "title": "Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105",
      "status": "UNKNOWN",
      "last_update": "2022-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05312398",
      "title": "CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05328908",
      "title": "A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2026-08-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05382741",
      "title": "Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial",
      "status": "UNKNOWN",
      "last_update": "2023-05-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05425940",
      "title": "Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05426811",
      "title": "Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2022-06-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05485909",
      "title": "Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM",
      "status": "UNKNOWN",
      "last_update": "2022-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05524155",
      "title": "Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis",
      "status": "UNKNOWN",
      "last_update": "2022-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05582031",
      "title": "Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers",
      "status": "WITHDRAWN",
      "last_update": "2023-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05600309",
      "title": "A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study",
      "status": "COMPLETED",
      "last_update": "2025-11-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05608044",
      "title": "A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05672316",
      "title": "Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05730673",
      "title": "Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2023-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05731947",
      "title": "Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-07-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05818267",
      "title": "Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)",
      "status": "UNKNOWN",
      "last_update": "2023-07-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05894837",
      "title": "Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases",
      "status": "UNKNOWN",
      "last_update": "2023-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05900648",
      "title": "Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)",
      "status": "WITHDRAWN",
      "last_update": "2024-04-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05933980",
      "title": "Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05970705",
      "title": "Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC",
      "status": "UNKNOWN",
      "last_update": "2023-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06006923",
      "title": "Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2026-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06071052",
      "title": "TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens",
      "status": "COMPLETED",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06089330",
      "title": "A Study of JMT101 in Patients With Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06199973",
      "title": "Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06200363",
      "title": "A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-01-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06283134",
      "title": "A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06283303",
      "title": "A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-02-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06322563",
      "title": "Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC",
      "status": "UNKNOWN",
      "last_update": "2024-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06543836",
      "title": "ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-08-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06575725",
      "title": "Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2024-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06856590",
      "title": "ZINCLO-HAND: Zinc and Clobetasol for the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction",
      "status": "COMPLETED",
      "last_update": "2025-09-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06865521",
      "title": "Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07134205",
      "title": "The Study of JMT101 Combined With Irinotecan as a \u22653rd-Line Treatment in Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07137390",
      "title": "A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2026-03-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07223567",
      "title": "A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer",
      "status": "WITHDRAWN",
      "last_update": "2026-02-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07353268",
      "title": "Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07384377",
      "title": "JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07483684",
      "title": "A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07535632",
      "title": "SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07730489",
      "title": "A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07750041",
      "title": "A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "REPOTRECTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03093116",
      "title": "A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",
      "status": "RECRUITING",
      "last_update": "2026-05-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SAPITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01862003",
      "title": "Phase I/II Trial of Antagonism of HER in GI Cancer",
      "status": "COMPLETED",
      "last_update": "2019-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SERABELISIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04073680",
      "title": "A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2020-05-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SIREMADLIN": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02890069",
      "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",
      "status": "COMPLETED",
      "last_update": "2023-01-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03714958",
      "title": "Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type",
      "status": "COMPLETED",
      "last_update": "2023-09-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SORAFENIB": {
    "n": 19,
    "n_observational": 3,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00134069",
      "title": "Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2014-04-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00326495",
      "title": "BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00703638",
      "title": "Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-11-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00779311",
      "title": "A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2011-11-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00780169",
      "title": "Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00826540",
      "title": "Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00839111",
      "title": "Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment",
      "status": "UNKNOWN",
      "last_update": "2010-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00865709",
      "title": "Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects",
      "status": "COMPLETED",
      "last_update": "2014-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00869570",
      "title": "External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer",
      "status": "COMPLETED",
      "last_update": "2019-05-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00889343",
      "title": "Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2013-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00989469",
      "title": "Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation",
      "status": "COMPLETED",
      "last_update": "2026-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01183663",
      "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)",
      "status": "COMPLETED",
      "last_update": "2016-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01290926",
      "title": "Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2016-02-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01376453",
      "title": "Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer",
      "status": "COMPLETED",
      "last_update": "2016-09-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01383343",
      "title": "Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2017-04-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01471353",
      "title": "Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2020-07-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01703910",
      "title": "Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic",
      "status": "COMPLETED",
      "last_update": "2015-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01715441",
      "title": "Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors",
      "status": "COMPLETED",
      "last_update": "2026-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03251612",
      "title": "Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SOTORASIB": {
    "n": 6,
    "n_observational": 0,
    "n_active": 5,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05845450",
      "title": "Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06252649",
      "title": "Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-na\u00efve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06645236",
      "title": "DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen\u00ae KRAS RGQ PCR Kit",
      "status": "RECRUITING",
      "last_update": "2025-08-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05198934",
      "title": "Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation",
      "status": "COMPLETED",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07124884",
      "title": "5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07318389",
      "title": "ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TASELISIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TOVORAFENIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04985604",
      "title": "Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07121829",
      "title": "Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-08-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TRASTUZUMAB": {
    "n": 59,
    "n_observational": 4,
    "n_active": 30,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT05253651",
      "title": "A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05672524",
      "title": "A Study of Tucatinib and Trastuzumab in People With Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05725200",
      "title": "Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2023-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05786716",
      "title": "DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations",
      "status": "RECRUITING",
      "last_update": "2025-12-02",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05824975",
      "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)",
      "status": "RECRUITING",
      "last_update": "2024-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05845450",
      "title": "Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05868226",
      "title": "PRE-ISPY Phase I/II Oncology Platform Program",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06245356",
      "title": "Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-12-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06253871",
      "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06324357",
      "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06490536",
      "title": "The Sagittarius Trial",
      "status": "RECRUITING",
      "last_update": "2025-08-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06589830",
      "title": "TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06625775",
      "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07108127",
      "title": "Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07216105",
      "title": "FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07407465",
      "title": "Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.",
      "status": "RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003995",
      "title": "Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2",
      "status": "COMPLETED",
      "last_update": "2013-02-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004074",
      "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu",
      "status": "COMPLETED",
      "last_update": "2013-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005842",
      "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006015",
      "title": "Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2013-05-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01376505",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-09-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01445054",
      "title": "111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer",
      "status": "TERMINATED",
      "last_update": "2019-03-11",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02291289",
      "title": "A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)",
      "status": "COMPLETED",
      "last_update": "2024-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02318901",
      "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer",
      "status": "TERMINATED",
      "last_update": "2019-10-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03043313",
      "title": "Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03185988",
      "title": "Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System",
      "status": "UNKNOWN",
      "last_update": "2019-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03225937",
      "title": "Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03288987",
      "title": "Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2021-01-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03319459",
      "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2021-11-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03323424",
      "title": "Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers",
      "status": "WITHDRAWN",
      "last_update": "2020-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03365882",
      "title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2026-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03384940",
      "title": "DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)",
      "status": "COMPLETED",
      "last_update": "2021-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03418558",
      "title": "Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.",
      "status": "UNKNOWN",
      "last_update": "2018-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03457896",
      "title": "Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status",
      "status": "UNKNOWN",
      "last_update": "2022-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03803553",
      "title": "Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03843749",
      "title": "Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.",
      "status": "UNKNOWN",
      "last_update": "2019-02-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04278144",
      "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-09-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04380012",
      "title": "A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2021-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04430738",
      "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04464967",
      "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers",
      "status": "WITHDRAWN",
      "last_update": "2021-05-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04482309",
      "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04579380",
      "title": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644068",
      "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04704661",
      "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04744831",
      "title": "Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05062889",
      "title": "Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients",
      "status": "SUSPENDED",
      "last_update": "2026-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05091528",
      "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers",
      "status": "TERMINATED",
      "last_update": "2022-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05193292",
      "title": "Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2022-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05356897",
      "title": "Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study",
      "status": "WITHDRAWN",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05395052",
      "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05515796",
      "title": "Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors",
      "status": "COMPLETED",
      "last_update": "2026-04-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06136897",
      "title": "Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06328738",
      "title": "ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07059338",
      "title": "Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07318389",
      "title": "ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07631884",
      "title": "Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07691489",
      "title": "A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07796763",
      "title": "A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TRASTUZUMAB DERUXTECAN": {
    "n": 13,
    "n_observational": 2,
    "n_active": 10,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05824975",
      "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)",
      "status": "RECRUITING",
      "last_update": "2024-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05845450",
      "title": "Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05868226",
      "title": "PRE-ISPY Phase I/II Oncology Platform Program",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06324357",
      "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07407465",
      "title": "Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.",
      "status": "RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03384940",
      "title": "DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)",
      "status": "COMPLETED",
      "last_update": "2021-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04482309",
      "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644068",
      "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04704661",
      "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04744831",
      "title": "Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05091528",
      "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers",
      "status": "TERMINATED",
      "last_update": "2022-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07318389",
      "title": "ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07691489",
      "title": "A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TRASTUZUMAB EMTANSINE": {
    "n": 5,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06324357",
      "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02318901",
      "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer",
      "status": "TERMINATED",
      "last_update": "2019-10-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03225937",
      "title": "Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03418558",
      "title": "Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.",
      "status": "UNKNOWN",
      "last_update": "2018-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TUCATINIB": {
    "n": 12,
    "n_observational": 0,
    "n_active": 8,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05253651",
      "title": "A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05672524",
      "title": "A Study of Tucatinib and Trastuzumab in People With Rectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05868226",
      "title": "PRE-ISPY Phase I/II Oncology Platform Program",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03043313",
      "title": "Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2024-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04430738",
      "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04579380",
      "title": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05062889",
      "title": "Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients",
      "status": "SUSPENDED",
      "last_update": "2026-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05091528",
      "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers",
      "status": "TERMINATED",
      "last_update": "2022-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05356897",
      "title": "Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study",
      "status": "WITHDRAWN",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05382364",
      "title": "Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07318389",
      "title": "ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07768358",
      "title": "Tucatinib Continuation Study",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VANDETANIB": {
    "n": 8,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00436072",
      "title": "ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2012-10-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00454116",
      "title": "A Phase II, Double Blind Study of 2 Doses of ZACTIMA\u2122(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients",
      "status": "COMPLETED",
      "last_update": "2016-10-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00496509",
      "title": "Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2016-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00499850",
      "title": "Phase I FOLFOX Combination",
      "status": "COMPLETED",
      "last_update": "2016-08-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00500292",
      "title": "A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2018-01-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00507091",
      "title": "Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination",
      "status": "COMPLETED",
      "last_update": "2016-08-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00532909",
      "title": "Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2012-07-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03291379",
      "title": "Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-07-19",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VEMURAFENIB": {
    "n": 15,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05768178",
      "title": "DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.",
      "status": "RECRUITING",
      "last_update": "2025-11-24",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06008119",
      "title": "Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06603376",
      "title": "Irinotecan Hydrochloride Liposome Injection (\u2161) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer",
      "status": "RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00405587",
      "title": "Safety Study of PLX4032 in Patients With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-08-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01787500",
      "title": "Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01791309",
      "title": "Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2016-01-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02164916",
      "title": "S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2020-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02291289",
      "title": "A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)",
      "status": "COMPLETED",
      "last_update": "2024-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03176485",
      "title": "Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors",
      "status": "COMPLETED",
      "last_update": "2019-01-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03727763",
      "title": "Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)",
      "status": "UNKNOWN",
      "last_update": "2021-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04790448",
      "title": "Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2023-02-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05019534",
      "title": "Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2022-05-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05233332",
      "title": "Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)",
      "status": "UNKNOWN",
      "last_update": "2023-05-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05540951",
      "title": "VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer",
      "status": "UNKNOWN",
      "last_update": "2022-09-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07714447",
      "title": "Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VOXTALISIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01390818",
      "title": "Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-03-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "XL-281": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00451880",
      "title": "Study of XL281 in Adults With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2011-10-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01086267",
      "title": "Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2016-06-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ZALUTUMUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00677924",
      "title": "Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer",
      "status": "TERMINATED",
      "last_update": "2023-07-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ZANIDATAMAB": {
    "n": 9,
    "n_observational": 0,
    "n_active": 8,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05868226",
      "title": "PRE-ISPY Phase I/II Oncology Platform Program",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06253871",
      "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06324357",
      "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06695845",
      "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07192068",
      "title": "Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.",
      "status": "RECRUITING",
      "last_update": "2025-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07405476",
      "title": "Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment",
      "status": "RECRUITING",
      "last_update": "2026-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03929666",
      "title": "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-09-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07243938",
      "title": "Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-11-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07631871",
      "title": "An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ZENOCUTUZUMAB": {
    "n": 0,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": []
   }
  }
 }
}